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The important thing is not to stop questioning. Curiosity 
has its own reason for existing. One cannot help but be in 
awe when he contemplates the mysteries of eternity, of 
life, of the marvelous structure of reality. It is enough if 
one tries merely to comprehend a little of this mystery 
every day. Never lose a holy curiosity.  
       
       Albert Einstein (1879 - 1955)  
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Summary 
 
The measurement of metabolism-related processes in vivo is a critical prerequisite for a better 
understanding of brain metabolism and its relationship to the brain at work. For a long time it was 
supposed that blood-borne glucose was the sole energy substrate of brain cells and that it was 
metabolized by the neurons and the astrocytes more or less independently.  
Only during the last few decades did one begin to appreciate the compartmentalization of energy 
metabolism between neurons and astrocytes. The finding of an activity-dependent glutamate 
mediated activation of the astrocytic glycolysis to generate and release lactate has led to the idea 
of an astrocyte neuron lactate shuttle (ANLS). The ANLS hypothesis claims that neurons take up 
the astrocytic lactate and use it for oxidation. This hypothesis has provoked a vivid debate about 
lactate use of neurons as an energy substrate. 
 
This project aimed at measuring the kinetics of positron emitter labeled tracers for the investigation 
of specific metabolic compartments of the neuron-astrocyte unit. In vivo radiotracer studies are 
useful tools to estimate the exchange of specific substances between different compartments. 
They can be performed both in animals and humans. 
  
The project was divided into three main parts: 
First, astrocytic oxidative metabolism was investigated using 1-11C-acetate. It turned out that this is 
a promising tracer to investigate astrocytic oxidative metabolism in rats and humans. An increased 
radioactivity washout was found during brain activation pointing to an increase in astrocytic 
oxidative metabolism during increased synaptic activity. Different pharmacological interventions 
supported the hypothesis that the measured acetate turnover is indeed related to oxidative 
metabolism.  
In a second part, we focused on neuronal oxidative metabolism. Inspired by previous reports 
demonstrating preferential lactate uptake by neurons, we evaluated the newly synthesized 
radiotracer 1-11C-L-lactate with respect to its kinetic properties in the rodent brain and were able to 
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demonstrate its feasibility to quantify cerebral lactate oxidation in vivo. We could show increased 
cerebral - most probably neuronal - lactate oxidation during increased brain activity. We further 
hypothesize, that the kinetics of 1-11C-L-lactate is not only measuring lactate metabolism, but is in 
addition an indicator of total neuronal oxidative metabolism.  
 
In a final method-oriented part of the project, we introduced a novel high-sensitivity surface probe 
for the measurement of radiotracer concentration through the intact although thinned skull. We 
demonstrated its ability to measure glucose utilization and blood flow in the rat cerebral cortex. 
This new development potentially broadens the field of applications for beta probes compared to 
conventional intracortical beta scintillators. Due to its decreased invasiveness it was successfully 
applied in the conscious animal. 
 
In summary, we demonstrated the usefulness of radiotracer methods for the investigation of 
specific aspects of cerebral energy metabolism and improved the methodology of beta probes.  
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Zusammenfassung 
 
Mit radioaktiv markierten Substanzen können veschiedene Stoffwechselvorgänge im lebenden 
Organismus untersucht werden. Ein grosser Vorteil dieser Methode ist ihre Anwendbarkeit in 
Humanstudien mittels Positronenemissionstomographie. Viele Arbeiten benutzten 18F-
Fluorodeoxyglukose, ein radioaktiv markiertes Glukoseanalog, für die Messung des zerebralen 
Glukoseumsatzes. Dieser stellt ein globales Mass für die Energiestoffwechselvorgänge dar, 
erlaubt aber keine Aussagen über die involvierten zellulären Kompartimente. In den vergangenen 
Jahrzehnten wurde aber klar, dass der Hirnstoffwechsel in den Astrozyten und den Neuronen 
räumlich und zeitlich sequestriert ist. Gleichzeitig besteht eine enge Kooperation zwischen den 
beiden Zelltypen. Dies wurde mit der Formulierung der sogenannten Astrozyten-Neuronen-Laktat-
Shuttle Hypothese unterstrichen. Diese besagt, dass aktivitätsabhängig in den Astrozyten 
gebildetes Laktat von den Neuronen zur Energiegewinnung verwendet wird. 
Ziele dieses Projektes waren A) Charkterisierung der Gewebekinetik von radioaktiv markiertem 
Azetat und Laktat und B) Anwendung dieser Substanzen zur Untersuchung des astrozytären 
(Azetat) und neuronalen (Laktat) oxidativen Stoffwechsels. 
 
Es ist bekannt, dass Azetat vorwiegend von den Astrozyten aufgenommen wird. Wir stellten daher 
die Hypothese auf, dass mit radioaktiv markiertem Azetat der astrozytäre Stoffwechsel untersucht 
werden kann. Experimente mit verschiedenen pharmakologischen Interventionen zeigten, dass die 
Auswaschrate des radioaktiven Labels mit grosser Wahrscheinlichkeit ein Mass für die CO2 
Produktion und damit des Sauerstoffverbrauchs ist. Unter elektrischer Stimulation des Infraorbital-
Nervs stieg der so gemessene astrozytäre Sauerstoffverbrauch markant an.  
 
In Analogie zu den Azetat Experimenten untersuchten wir in einem zweiten Teil den neuronalen 
oxidativen Stoffwechsel mit markiertem Laktat (1-11C-L-Laktat). Grundlage dieser Experimente 
sind Hinweise, dass Laktat präferenziell von den Neuronen aufgenommen wird. Auch bei Laktat ist 
es wahrscheinlich, dass die Auswaschrate des Labels den oxidativen Stoffwechsel reflektiert. Die 
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Experimente zeigten wie bei Azetat einen markanten Anstieg der Labelauswaschrate unter 
Stimulation, welchen wir als gesteigerten neuronalen Sauerstoffverbrauch deuten.  
 
In einem letzten Teil der Arbeit ging es darum, die angewandte Messtechnik weiter zu verfeinern. 
Wir entwickelten eine Betasonde, mit welcher das Radioaktivitätssignal durch den 
Schädelknochen hindurch gemessen werden kann. Dieses neue Gerät ist etwa 20-mal sensitiver 
als das zuvor verwendete System. Dank dieser Sensitivitätssteigerung war es möglich, zwei 
Injektionen im selben Tier vorzunehmen, womit die Varianz der Daten erheblich gesenkt wurde. 
Als letztes konnten wir demonstrieren, dass mit der neuen Sonde Messungen am wachen Tier 
möglich sind.  
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List of definitions  
 
AIC = Akaiche information criterion  
A measure for the goodness of fit of an estimated statistical model. In Kinetic modeling it is used 
as a tool for model selection. Given a data set, several competing models are ranked according to 
their AIC, with the one having the lowest AIC being the most accurate. 
 
ANLSH = Astrocyte-neuron-lactate-shuttle hypothesis  
Present concept about the intercellular organization of brain energy metabolism and its coupling to 
synaptic activity. See page 19 and Figure 2 for explanation. 
 
AR = Autoradiography  
A method to determine the distribution of a radiolabeled ligand on tissue sections. See page 31 for 
further description of the methodology. 
 
ATP = Adenosine-5’-triphosphate 
Beside many other functions it is the most important ‘energy currency’ transported within cells. Net 
production during glucose degradation.  
 
BBB = Blood brain barrier 
A protective barrier formed by the blood vessels and glia of the brain. It prevents plenty of 
substances in the blood from entering the brain tissue. 
 
BOLD fMRI =  
Functional magnetic resonance imaging relying on the detection of intrinsic changes in 
haemoglobin oxygenation assumed to imply underlying neural activity. 
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CBF = Cerebral blood flow 
Blood supply to the brain in a given time. In an adult, CBF is typically about 15% of the cardiac 
output. 
 
CNS = Central nervous system 
It consists of the brain and the spinal cord and is enclosed in the meninges. It coordinates the 
neuronal activity of all parts of the body of a multicellular organism. 
 
EF = First pass extraction fraction 
The fraction of a radiotracer which is extracted from the brain during its first passage after injection. 
The EF is highly dependent on cerebral blood flow expressed by the equation EF = K1/CBF. 
 
FWHM = Fuel width at half maximum 
Image resolution of a PET scanner is determined by the FWHM of a point spread function.  
 
18F-FDG = 18F-fluorodeoxyglucose 
Analog of glucose labeled with fluorine-18 often used for the determination of glucose utilization in 
vivo using radiotracer methods such as PET. 
 
GABA = Gamma aminobutyric acid 
The main inhibitory neurotransmitter in the mammalian central nervous system. It plays an 
important role in regulating neuronal excitability throughout the nervous system.  
 
GLAST = Glutamate aspartate transporter 
One of the five glutamate transporters identified so far in the brain. It is also often called excitatory 
amino acid transporter 1 (EAAT1). It is highly expressed in astrocytes allowing them to be 
responsible for most of glutamate uptake during synaptic transmission. It mediates the transport of 
glutamate from the synaptic cleft with the cotransport of 3 sodium ions. This co-transport allows the 
Definitions 
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transport of glutamate against a concentration gradient into the cell. This is an important process to 
avoid excitatory damage in the brain.  
 
GLT-1 = Glial glutamate transporter  
It is also called excitatory amino acid transporter 2 (EAAT2). Like GLAST it is predominantly 
localized in astrocytes and responsible for sodium-dependent astrocytic glutamate upake. 
 
GLUT = Glucose transporter 
Twelve membrane-spanning domains containing proteins enabling the facilitative transport of 
glucose across cell membranes. Actually 14 members have been identified.  GLUT1 (BBB and 
astrocytes) and GLUT3 (neurons) are the predominant cerebral glucose transporters. 
 
K1, k2, k3, .., kn = Rate constants 
Regularly used in kinetic modeling to describe the transfer of radiotracer between the 
compartments of a n/2-tissue compartment model. They are assumed to be linearly related to the 
concentration differences between two compartments. On pages 23 - 30 the principles are further 
explained.   
 
Km = Dissociation constant 
This is a commonly used parameter to describe the affinity between a ligand and a protein (e.g. 
receptor, transport protein). The dissociation constant has molar units, which corresponds to the 
concentration of a ligand at which the binding site is half occupied. The smaller the dissociation 
constant the higher the affinity of the ligand for its target site. 
 
LC = Lumped constant 
This constant calibrates for the differences in transport and phosphorylation rates between the 
glucose analog fluorodeoxyglucose and glucose in tissue. It is required for rigorous calculation of 
the glucose metabolic rate from radiotracer experiments using 18F-FDG. 
Definitions 
 
 
10 
 
LCMRglu = Local cerebral metabolic rate of glucose  
Number to quantify glucose utilization in the brain. Usually given in μmol/100g/min. 
 
LDH = Lactate dehydrogenase 
This enzyme catalyzes the conversion of pyruvate to lactate and vice versa. LDH is a rate-limiting 
enzyme in lactate fluxes. In vertebrates 5 isoforms are so far identified. In brain especially LDH-1 
(present in neurons) and LDH-5 (enriched in astrocytes) play an important role. 
 
MCT = Monocarboxylate transporter 
Proton-linked transporters located at the plasma membrane responsible for the transport of 
monocarboxylic acids such as lactate. At least 9 MCTs-related genes have so far been identified in 
mammals. 
 
MRS = Nuclear magnetic resoncance spectroscopy 
A method exploiting the magnetic properties of certain nuclei. It has proven a unique tool for the 
measurement of metabolic fluxes in brain. Read page 39 for more details.  
 
NAD+/NADH = Nicotinamide adenine dinucleotide 
A coenzyme found in all living cells. In metabolism, NAD+/NADH are involved in redox reactions 
carrying electrons from one reaction to another. 
 
NADPH = Nicotinamide adenine dinucleotide phosphate 
In cells of the brain, as in other organs, this reduced substrate provides the reducing power. In 
addition, NADPH is needed for the scavenging of reactive oxygen species. 
 
PET = Positron emission tomography 
A non-invasive nuclear medicine imaging technique often applied in human neuroimaging. It 
produces three-dimensional images of functional processes. On pages 34 -35 the method is 
introduced in detail. 
Definitions 
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RQ = Respiratory quotient 
The RQ is calculated from the ratio CO2 produced/ O2 consumed. The range of RQ for humans usually 
ranges from 1.0 (representing pure carbohydrate oxidation) to ~0.7 (representing pure fat 
oxidation). 
 
TAC = Time activity curve 
Curves obtained by kinetic radiotracer experiments describing the radioactivity concentration in the 
tissue under study over time. 
 
TCA cycle = Tricarboxylic acid cycle (syn. Krebs’ cycle) 
Part of the metabolic pathway involved in the oxidative degradation of carbohydrates, fats and 
proteins into carbon dioxide and water to produce energy. The TCA cycle occurs in the matrix of 
mitochondria.  It is also known as the citric acid cycle. 
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Introduction 
 
The main function of the brain consists of dealing with information. This involves transfer, 
processing and exchange of information. The work of the brain is closely linked to metabolism, i.e. 
changes in the electrical activity of neurons are tightly coupled to changes in metabolic substrate 
use and local blood flow (for a review see (Raichle and Mintun 2006)). The tight connection of 
electrical activity to physiological processes such as blood flow was already postulated more than 
one century ago in a seminal work by (Roy and Sherrington 1890). This relationship forms the 
basis of functional neuroimaging methods such as positron emission tomography (PET; Reivich et 
al. 1977; Reivich et al. 1979) and functional magnetic resonance imaging (fMRI; Ogawa et al. 
1992). These two techniques are the most widely used methods in the field of brain imaging today, 
underlined by an enormous number of publications in this field. Whereas fMRI measures signals 
related to haemodynamics and oxygen consumption – known as blood oxygen level dependent 
(BOLD) signals, PET is able to investigate a variety of different pathways and compartments. This 
capability of PET mainly depends on the radiotracers used. For the study of brain energy 
metabolism especially 18F-fluorodeoxyglucose (18F-FDG) has been used extensively up to date. 
Originally the method of determining glucose utilization using radiolabeled glucose analogues was 
introduced by Sokoloff for the use in rodents (1977) together with autoradiography and was later 
refined for the application in humans using PET (Reivich et al. 1977; Reivich et al. 1979). The 
approach gives an excellent regional metabolic differentiation, but it does not distinguish between 
different compartments such as neuronal and glial cells. However, such compartmental 
differentiation is of major importance to make a step further in the current understanding of 
mechanisms and relationships underlying brain energy metabolism. Today, it is widely accepted 
that brain metabolism is compartmentalized not only on a cellular level between neurons and glial 
cells, but also on a subcellular level e.g. between tricarboxylic acid (TCA) cycle in mitochondria 
and anaerobic glycolysis in the cytoplasm of the cells (Hertz 2004).  
The current thesis project mainly aims at evaluating new approaches to measure distinct metabolic 
compartments in the brain (i.e. oxidative metabolism in neurons and astrocytes) based on the 
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measurement of radiotracer kinetics. In this context the following introduction reviews the central 
concepts and fundamentals about brain metabolism and its measurement using radiotracer 
methods. 
 
 
Brain energy metabolism 
Benchmark data of the brain 
The brain is an organ that displays high metabolic activity, which manifests itself in remarkable 
numbers. Although it claims only ~2% of body weight, it receives ~15% of the cardiac output and 
accounts for about 20% of total body oxygen consumption, as well as 25% of total body glucose 
utilization. Already these proportions demonstrate that cerebral energy metabolism and energy 
budgeting play an important role. This becomes even clearer if one considers that brain functions 
arrest after 2 minutes of interrupted blood circulation and that consciousness is lost already after 
approximately 15 seconds of oxygen deprivation. The size of the endogenous stores of energy 
substrates is the main reason for this dependence. Compared to their rates of utilization, they are 
small and their turnover rates are slow (Choi et al. 2003; Watanabe and Passonneau 1973). For 
example, glycogen reserves are about 10 to 100 times smaller than in the liver (Brown and 
Ransom 2007). 
  
Brain metabolism 
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Present concepts of brain energy metabolism 
Glucose: The major energy fuel 
The respiratory quotient (RQ), which is calculated from the ratio CO2 produced/O2 consumed, helps to 
make a statement about the composition of the diet an organ consumes. The ranges of RQs go 
from 1.0 (representing complete carbohydrate diet) to ~0.7 (expected for pure fat oxidation). The 
RQ of the brain is close to 1, indicating that carbohydrates are the main substrates of cerebral 
oxidative metabolism. For a long time blood-borne glucose was regarded to represent the major 
and only energy substrate for the brain supporting neuronal activity (Siesjo 1978; Sokoloff 1989). 
Glucose crosses the vascular endothelial cells and enters the brain cells via specific facilitative 
glucose transporters (GLUT) along its concentration gradient (McEwen and Reagan 2004; 
Vannucci et al. 1998; Vannucci et al. 1997).  The two main isoforms of glucose transporters found 
in brain are GLUT1 and GLUT3 (Maher et al. 1993; Maher et al. 1994). GLUT1 is present in two 
isoforms, namely in a highly glycolysated form (55 kDa) at the blood brain barrier (BBB) and in a 
less glycosylated form (45 kDa) predominantly present in glial parenchyma (Morgello et al. 1995). 
The isoform GLUT3 is present mainly in neurons (Maher et al. 1993; Maher et al. 1994). GLUT 
density and therewith glucose transport increase upon stimulation by glutamate within the range of 
a few seconds. This represents the fastest stimulation of mammalian glucose transport known to 
date (Duelli and Kuschinsky 2001; Loaiza et al. 2003). Following this first step in glucose 
utilization, glucose is processed via the same pathways as in other tissues. This includes its 
sequential degradation in cytosolic glycolysis and oxidative metabolism in the mitochondria 
resulting in complete degradation to CO2 and H2O (Figure 1).  
One molecule of glucose yields 38 molecules of the energy fuel adenosine triphosphate (ATP) 
during complete oxidation. However, the relative contribution of neuronal and astrocytic glycolysis 
and respective TCA cycle activities to the total cerebral energy budget is not clear at present and 
highly controversial. Beside its role as energy fuel, glucose also serves as a precursor by entering 
several biochemical pathways. Glucose plays an important role in the synthesis of the three key 
neurotransmitters of the brain (gamma amino butyric acid (GABA), glutamate and acetylcholine 
(anaplerotic reactions)) as well as in the pentose phosphate pathway that provides nicotinamide 
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adenine dinucleotide phosphate (NADPH) needed for the scavenging of reactive oxygen species. 
 
Figure 1. Main metabolic pathways involved in the degradation of glucose for the generation of 
energy 
        (See figure legend on the next page.)
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In the upper part of the scheme (light blue background) the glycolysis – anaerobic degradation of glucose to 
pyruvate/lactate - is shown. Phosphorylation to glucose by hexokinase is the first regulation step. This 
enzyme is inhibited by glucose-6-phosphate. In addition the possibility of glucose storage as glycogen is 
indicated (in the brain this is only known to occur to a limited extent in astroytes). 
Two other important steps in the regulation of glycolysis are the steps catalyzed by the enzymes 
phosphofructokinase and pyruvate kinase. Their activity is controlled by adenosine triphosphate (ATP), 
citrate and acetyl CoA. Pyruvate is in equilibrium with lactate catalyzed by lactate dehydrogenase (lactate 
DH) and regenerating NAD+ which is necessary to sustain glycolysis after glyceraldehyde 3-phosphate. 
The lower part of the diagram (light green background) depicts the tricarboxylic acid cycle (syn. Krebs’ cycle) 
with its substrates. Pyruvate dehydrogenase (Pyruvate DH) decarboxylates pyruvate to acetyl CoA, which 
enters the cycle by reacting with oxaloacetate to citrate. Pyruvate dehydrogenase activity is inhibited by ATP 
and NADH. In addition, the link to the glutamate/glutamine cycle, which plays an important role in the 
interplay of astrocytes and neurons, and the oxidative phosphorylation downstream of the TCA cycle are 
added (for details see main text). 
 
 
Use of alternative substrates 
Under special conditions the brain has the capability to use energy substrates other than glucose. 
The mammalian brain contains transport mechanisms that allow alternative substrates such as 
lactate to cross the BBB via specialized monocarboxylate transporters (MCT). Recently an 
additional Na+-coupled transport system in neurons for L-lactate, short-chain fatty acids and 
ketone bodies was described (Martin et al. 2006b).  
In breast-fed newborns and suckling rats the utilization of ketone bodies and monocarboxylates by 
the brain is increased (Cremer 1982; Cremer et al. 1979; Dombrowski et al. 1989; Hawkins et al. 
1971; Nehlig and Pereira de Vasconcelos 1993). A few studies have also suggested under certain 
circumstances monocarboxylates and ketone bodies can represent energy substrates for the adult 
brain. In the case of prolonged starvation and diabetes, an increase in brain ketone bodies 
utilization has been documented (Gjedde and Crone 1975; Hawkins et al. 1986; Mason et al. 2006) 
and monocarboxylic acid transport in the brain is increased about twofold in patients with Diabetes 
Type I during hypoglycaemia (Mason et al. 2006). Net lactate utilization by the brain was also 
reported during and after exercise-induced (Dalsgaard and Secher 2007; Ide et al. 2000) and 
artificially induced hyperlactatemia (Smith et al. 2003). The discussion about lactate use of the 
normal mammalian brain has become especially vivid after the formulation of the astrocyte-neuron 
lactate shuttle hypothesis (see below). 
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Compartmentation of brain metabolism  
In parallel to the discovery of possible alternative substrate use by brain cells the finding of 
metabolic compartmentation in the central nervous system (CNS) received increased attention. 
Already forty years ago distinct compartments in brain metabolism were suggested. It was stated 
that at least two compartments were involved (two distinct TCA cycles) (Berl et al. 1970; Berl et al. 
1968). Using 14C labeled substrates a large and a small glutamate pool were postulated. One TCA 
cycle metabolizes acetate and is associated with a small pool of glutamate which is the precursor 
of glutamine, the so-called ‘small’ compartement (its TCA cycle was termed ‘synthetic’ with 
reference to the synthesis of glutamine). The second TCA cycle, more or less inaccessible to 
acetate and not associated with glutamine synthesis, was termed ‘large’ compartment (Berl et al. 
1970; Berl and Frigyesi 1969; Cremer 1970; Van den Berg et al. 1969; Van den Berg and Ronda 
1976). Using immunohistochemical studies the small compartment was identified eventually as 
astrocytic and the large as neuronal (Martinez-Hernandez et al. 1977; Minchin and Beart 1975a; 
Minchin and Beart 1975b; Norenberg and Martinez-Hernandez 1979). Moreover, 
compartmentation was discovered to be at least in part due to the different enzymatic equipment of 
neurons and astrocytes. Glutamine synthetase was found to be localized specifically in astrocytes 
(Martinez-Hernandez et al. 1977; Norenberg and Martinez-Hernandez 1979) whereas the enzyme 
glutaminase is primarily enriched in neurons (Cangro et al. 1984).  
During the last decade the evidence about the highly compartmentalized metabolism in brain 
tissue further increased and the interest in the function of the astrocytes in this interplay entered 
the scene of neuroscience (Hertz 2004; Hertz et al. 2007; Volterra and Meldolesi 2005). The 
astrocytes were now regarded as active and important partners of neuronal cells in the metabolic 
cooperation. It has been found that the metabolic compartments are active in a highly regulated 
and concentrated manner dependent on neuronal activity. Recently Kasischke et al. were able to 
resolve metabolic signatures in processes of astrocytes and neurons using an elegant approach 
with two-photon microscopic fluorescence imaging of nicotinamide adenine dinucleotide (NADH) in 
brain tissue slices (Kasischke et al. 2004). They found a spatiotemporal separation of glycolytic 
and oxidative metabolism between astrocytes and neurons during increased neural activity, 
supporting the idea of a highly regulated team work between neurons and astrocytes. This tight 
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metabolic cooperation was postulated previously as the astrocyte-neuron lactate shuttle 
hypothesis. 
 
Astrocyte-neuron lactate shuttle hypothesis 
About 15 years ago it was for the first time postulated that lactate, produced preferentially by the 
astrocytes, is shuttled via specific monocarboxylic acid transporters (MCT) from the astrocytes to 
active neurons (Magistretti and Pellerin 1999; Magistretti et al. 1999; Pellerin and Magistretti 1994) 
where it is subsequently oxidized in the TCA cycle (Figure 2). This process was termed the 
astrocyte-neuron lactate shuttle (ANLS) and the ANLS hypothesis provoqued a heated debate in 
the Neuroscience community that still lasts today (Bonvento et al. 2005; Chih et al. 2001; Chih and 
Roberts Jr 2003; Kimelberg 2004; Pellerin and Magistretti 2003; Schurr 2005).  
 
Figure 2. Concept of the astrocyte-neuron lactate shuttle hypothesis (ANLSH)  
Simplified schematic of the major mechanisms involved in the tight coupling between neuronal activity and 
brain metabolism. Activation of glutamatergic afferents leads to presynaptic release of glutamate which  
activates postsynaptic ionotropic glutamate receptors (NMDA, AMPA). To determine glutamatergic action the 
 
         (continuation on page 20) 
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(continuation from page 19) 
 
neurotransmitter is mainly taken up by astrocytes from the synaptic cleft via the specific glutamate 
transporters GLT-1 and GLAST (Danbolt 2001). The large accompanying Na+ influx activates the Na+/K+ -  
ATPase, glucose transport and glucose utilization in astrocytes leading to conversion of pyruvate into lactate. 
Lactate is released via monocarboxylate transporters (MCT1 and 4) into the extracellular space and from 
there taken up by the neurons (MCT2) whom it serves as an energy substrate. After uptake into astrocytes 
glutamate is converted to glutamine by the astrocyte-specific enzyme glutamine synthetase (GS; Martinez-
Hernandez et al., 1977) and transported back to neurons. For further details see text. (Further abbreviations 
in the figure: GLUT1, GLUT3: glucose transporters; LDH1, LDH5: lactate dehydrogenases; TCA cycle: 
tricarboxylic acid cycle; Ac-CoA: acetyl-CoA; Pyruvate – DH: pyruvate dehydrogenase; PAG: phosphate 
activated glutaminase) 
 
Basically, the hypothesis summarizes a whole chain of events involved in the coupling of neuronal 
and metabolic activity. In detail, it describes the following processes: During increased synaptic 
activity glutamatergic neurons release the neurotransmitter glutamate into the synaptic cleft. From 
there it is avidly taken up by the astrocytes via specific glial glutamtate transporters (EAAT1 or 
GLAST and EAAT2 or GLT-1) in cotransport with sodium ions (Danbolt 2001). This cotransport of 
sodium ions leads to an increase in the intracellular sodium concentration which activates energy-
dependent Na+/K+-ATPases. The corresponding hydrolysis of ATP leads to an activation of the 
astrocytic glycolysis, i.e. the degradation of glucose to pyruvate and via lactate dehydrogenase to 
lactate. According to the ANLS theory most of the lactate produced in the astrocytes is released 
via specific MCT into the extracellular space and from there it is taken up by the neurons via a 
different isoform of MCT (Broer et al. 1999; Broer et al. 1997; Froberg et al. 2001; Gerhart et al. 
1998; Gerhart and Leino 1999; Halestrap and Price 1999; Pierre et al. 2002).  
The hypothesis is based on numerous findings. Most of them were established in in vitro 
preparations. Already the distribution of the specific MCTs and their affinity for lactate favors export 
of lactate from astrocytes and uptake by neurons (Debernardi et al. 2003; Pellerin et al. 1998; 
Pierre and Pellerin 2005). Astroglial cells predominantly express low affinity MCTs (MCT1 with a 
dissociation constant (Km) for lactate of 3.5 – 8 mmol/l (Broer et al. 1997) and MCT4 with a Km of 
35 mmol/l (Dimmer et al. 2000)). In contrast, neurons express predominantly high affinity MCTs 
(MCT2 with Km of 0.7 mmol/l (Broer et al. 1999)). A second finding that supports the ANLS 
hypothesis is the distribution of lactate dehydrogenases (LDH). The enzyme catalyzing the 
reaction from pyruvate to lactate and vice versa exists in different isoforms. The two subtypes 
found in the brain are LDH1 and LDH5. LDH1 (heart-type LDH; inhibited by pyruvate) which 
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preferentially catalyzes the reaction from lactate to pyruvate is specific to neurons, whereas LDH5 
(muscle-type LDH; present in glycolytic tissues) catalyzes the step from lactate to pyruvate and is 
predominantly found in astrocytes (Bittar et al. 1996; Laughton et al. 2000). In summary, the 
equipment of the different players in the neuro-glial cooperation is such, that a lactate flux from 
astrocytes to neurons is favored. 
Support for the ANLS hypothesis also comes from cell culture experiments demonstrating a 
preferential use of lactate compared to glucose by neurons (Bouzier-Sore et al. 2003b; Itoh et al. 
2003; Larrabee 1983; Larrabee 1995; Larrabee 1996; McKenna et al. 2001). In recent days there 
has been increasing evidence for the ANLS from in situ experiments in brain slices. One of the 
recent and most often cited works in this context is the aforementioned study by Kasischke et al. 
which elegantly showed the temporal sequence of several metabolic events using two-photon 
fluorescence imaging of nicotinamide adenine dinucleotide (2004). The authors were able to 
demonstrate that neuronal oxidative metabolism is followed by astrocytic glycolysis during focal 
neural activity. 
However, there still is a vivid debate about the contribution of the single compartments and about 
the validity of the lactate shuttle between astrocytes and neurons in the brain. One of the main 
reasons for the ongoing controversy is the fact that evidence for the ANLS hypothesis is still based 
mainly on in vitro experimental findings. Results obtained in ‘artificial’ preparation might not reflect 
the situation in the intact brain. Since the formulation of the hypothesis more than one decade ago 
there still is insufficient in vivo support for the processes involved in the ANLS. However, there 
exists some indirect in vivo evidence for the concept. Smith and coworkers used glucose utilization 
measurements with 18F-fluorodeoxyglucose positron emission tomography in healthy volunteers. 
An increase of the blood lactate concentration led to a decrease of total cerebral glucose 
metabolism (Smith et al. 2003). This was interpreted as indirect evidence for the preferential use of 
lactate by the neurons. At the same time a complementary approach was applied in rats. Using 
dichloroacetate for the pharmacological activation of the pyruvate dehydrogenase activity, lactate 
production of astrocytes was decreased which evoked increased baseline cerebral glucose 
utilization (Itoh et al. 2003). This finding further supports the compartmentalization of the glucose 
metabolism between astrocytes and neurons. Furthermore, Serres and colleagues presented data 
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from nuclear magnetic resonance spectroscopy studies demonstrating that there is production of 
lactate within the brain parenchyma through glycolysis which originates from a cellular 
compartment other than neurons (Serres et al. 2004; Serres et al. 2005; Serres et al. 2003), but 
they were not able to clearly identify the exact origin. Just recently a study was published where 
changes of neuronal, astrocytic and extracellular pH values were taken as evidence for the 
shuttling of lactate between astrocytes and neurons (Erlichman et al. 2008). In addition, in other 
tissues, such as testis and skeletal muscle, lactate shuttles also have been described some years 
ago (Brooks 2002) indicating that lactate shuttles may present a more general principle in 
organisms. 
However, all these studies offer only indirect support for the shuttling of lactate from the astrocytes 
to the neurons and new approaches for investigating aspects of brain energy metabolism are 
desirable. 
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Common in vivo neuroimaging methods in the field of 
brain metabolism 
 
Theoretical considerations about radiotracer experiments and their 
analysis 
 
In the first part of this section the theoretical and technical principles of radiotracer experiments 
and the most common radiotracer techniques (positron emission tomography (PET), beta probe 
studies, autoradiography (AR) are explained in detail because their theory forms the basis of this 
work. Radiotracer methods can measure organ distributions (AR, PET) and time courses (PET, 
beta probe studies) of local tracer concentrations. Using PET and beta probes in vivo experiments 
can be performed. This leads to more realistic experimental conditions than in isolated organ 
preparations, which are occasionally used to generate kinetic tracer data. In in vivo experiments 
not only the effect of tracer recirculation but also the influence of other body organs is included 
(e.g. metabolism of the radiotracer in the liver, binding of radiotracer in other organs etc.), which 
can strongly affect tracer kinetics in the organ under investigation. In general, experiments in the 
intact organism provide a more realistic environment for testing the adequacy of a model to 
describe tracer kinetics. 
Beside radiotracer methods there obviously exist several other methodologies to investigate 
aspects of brain metabolism. Examples are nuclear magnetic resonance spectroscopy, A-V 
difference measurements and microdialysis studies. Some of these methods will be compared to 
the radiotracer methods in the second part of this chapter and major issues will be discussed. 
 
General requirements for a radiotracer 
To exploit the quantitative capabilities of radiotracer kinetic measurements, data has to be 
analyzed using appropriate methods. In the next sections an overview will be given about the 
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concepts applied to analyze radiotracer kinetic data. Besides the obvious requirement to cross the 
BBB, there are several further general prerequisites which a new tracer must fulfill to be feasible 
for brain studies. Firstly, the tracer must be related predominantly to the process of concern. 
Secondly, the kinetics of the tracer in the tissue must be within the time window of the 
measurement and the radioactivity decay time of the labeling isotope. In addition, ideally there 
should be no metabolism of the labeled compound in blood. Finally, radiotracers have to be 
produced with high specific activity allowing the application of very small amounts to avoid 
unwanted pharmacological side effects. 
 
Concept of compartmental modeling for data analysis 
Data acquired with both PET and beta probes represent tracer concentration per tissue volume 
(kBq/cc). In most cases, tracer concentration cannot be directly transformed into quantitative 
parameters such as substrate utilization in μmol per tissue volume per minute or perfusion in ml 
per minute per 100 ml of tissue. However, such absolute quantification is superior to other 
quantification methods for e.g. group comparisons or monitoring of treatment effects. Beside an 
optimal tracer for the process studied and an optimized acquisition protocol, adequate data 
analysis tools are needed. Compartment models are widely used to describe biological processes 
in living organisms. Figure 3 shows the visualization of three different configurations of the 
classical compartment model using diagrams with rectangles to symbolize compartments and 
arrows representing the exchange of the tracer between the compartments. Linear compartmental 
models are the most commonly used tracer kinetic models for the analysis of radiotracer data. 
Compartments in the field of radiotracer imaging refer to a volume of the tissue, in which properties 
such as concentrations, metabolism and transport characteristics can be assumed to be 
homogeneous. That is, within a compartment the rate of exchange of a tracer is fast compared to 
the rate of exchange between different compartments and thus the tracer is instantaneously mixed 
within the compartment. Examples of frequently used compartments include: 
 
• Tracer in the arterial plasma  
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• Free tracer in tissue that can be bound or that may diffuse back into the blood 
• Tracer in the tissue that has been unspecifically bound to other than the targeted 
cell components  
• Tracer in tissue that has been specifically bound to the targeted cell component 
(e.g. receptor sites, enzymes)  
 
 
Blood compartment  
The first compartment in most models is the arterial blood. It is necessary to know the tracer 
concentration in the blood over time. After intravenous injection the tracer is transported to the 
heart where it is well mixed with blood and distributed throughout the body by the arterial 
circulation. Assuming that after this mixing all the arterial blood has the same tracer concentration, 
the concentration of tracer delivered to capillaries can be determined from any peripheral artery. 
Blood sampling at timed intervals is initiated with the onset of the tracer administration. In studies 
applying manual blood sampling, short intervals are chosen at the beginning to avoid missing the 
peak concentration of the tracer in arterial blood (10 – 20 second intervals). Sampling is continued 
at less frequent intervals later in the experimental period (up to 15 – 30 minute intervals). Arterial 
blood samples are then centrifuged to separate plasma from cells and measured using an 
appropriate device to determine the plasma concentration of the tracer. Tracer in the plasma is the 
fraction which is available for transfer into tissue and its dynamics is called arterial input curve. The 
time course of native tracer in plasma (= input curve; Cpl) is the driving force of tracer delivery to 
tissue and an important prerequisite for data analysis (see below). An increased number of studies 
use on-line blood sampling, which dramatically reduces the number of blood samples to be 
collected.  
The models assume first-order processes. This has the consequence that the change of tracer 
concentration in one of the compartments is a linear function of the concentrations in all other 
compartments. As mentioned above, it is also assumed that the observed system is not disturbed 
by the injected radioligand. This prerequisite is fulfilled by most tracer studies, because detection 
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devices used for radiotracer imaging studies have sensitivities of 10-11 – 10-12 mol/l, offering the 
possibility to inject tiny amounts of the tracer. 
 
Tissue compartment(s) 
Looking at a one-tissue compartment model (Figure 3A), the dependence of the concentration in 
the tissue compartment on the concentration of tracer in plasma can be illustrated. The tracer 
concentration in tissue increases due to the extraction of tracer from plasma. As this process is 
described by a first-order process, the transfer of material is proportional to the concentration in 
plasma (Cpl). At the same time it is reduced by a backward transfer, which is proportional to the 
concentration in the tissue (Ctiss). Both processes compete, so that the change of the tracer 
concentration in the tissue over time (dCtiss(dt)/t) can be expressed by the following differential 
equation: 
 
ௗ஼೟೔ೞೞ,భሺ௧ሻ
ௗ௧
 ൌ  ܭଵܥ௣௟ሺݐሻ െ ݇ଶ ܥ௧௜௦௦,ଵሺݐሻ     (1) 
 
The two rate constants (also called transfer coefficients), K1 and k2, have a somewhat different 
meaning, indicated by the use of capital and small letters. K1 includes a perfusion dependent 
component and has units of milliliter per minutes per milliliter of tissue, whereas k2 indicates the 
fraction of mass transferred per time (min-1). For example, if k2 has the value 0.1 min-1, the material 
leaves the compartment at a rate of 10% per minute. 
In addition, the more complex models shown in Figure 3B and 3C distinguish different forms of 
tracer in tissue. After entering a cell, the tracer is available in a free form at a concentration Ctiss,1. 
From this form, it can directly be bound to its target component of the cell Ctiss,2 (e.g. target 
receptor site, intracellular macromolecules etc.), but it also may bind to unspecific cell components, 
Ctiss,3. The differential equations for this model can be derived in analogy to the one-tissue 
compartment model, but are more complex. For example the equations for the model shown in 
Figure 3C are given by 
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ௗ஼೟೔ೞೞ,భሺ௧ሻ
ௗ௧
 ൌ  ܭଵܥ௣௟ሺݐሻ െ ሺ݇ଶ  ൅ ݇ଷ  ൅ ݇ହሻܥ௧௜௦௦,ଵሺݐሻ  (2) 
൅ ݇ସܥ௧௜௦௦,ଶሺݐሻ ൅ ݇଺ܥ௧௜௦௦,ଷሺݐሻ 
 
ௗ஼೟೔ೞೞ,మሺ௧ሻ
ௗ௧
 ൌ   ݇ଷܥ௧௜௦௦,ଵ  െ  ݇ସܥ௧௜௦௦,ଶሺݐሻ (3) 
  
 
ௗ஼೟೔ೞೞ,యሺ௧ሻ
ௗ௧
 ൌ   ݇ହܥ௧௜௦௦,ଵ  െ  ݇଺ܥ௧௜௦௦,ଷሺݐሻ (4) 
  
After the determination of radioactivity time courses in tissue (Ctiss) and in arterial plasma (Cpl) the 
parameters of a model (K1, k2, …, kn; with the number of rate constants depending on the number 
of compartments (see Figure 3)) are fitted such that the calculated tissue time activity curve (TAC) 
fits the measured values as adequately as possible.  
The amount of tracer delivered to tissue is affected by the blood flow. Once inside the capillary 
bed, some part of the tracer is extracted into the tissue. This fraction is called the first pass 
extraction fraction (EF). As mentioned above, for their delivery to the brain tissue (K1) all tracers 
initially depend on cerebral blood flow (CBF) even though blood flow may not be the process of 
primary interest. The relation  
 
ܭଵ   ൌ ܥܤܨ  ൈ ܧܨ  (5) 
 
illustrates this dependence. Renkin (1959) and Crone (1963) calculated the extraction as  
 
ܧܨ  ൌ 1  െ ݁ି௉ௌ ஼஻ி⁄  (6) 
 
where P denotes the capillary permeability and S the surface of the endothelium by which the 
capillary exchanges tracer with the tissue. 
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Figure 3. Examples for configurations of classic compartment models 
Rectangles display various compartments, arrows represent mass transfer between the compartments. A: 
One-tissue compartment model. B: Two-tissue compartment model. C: Three-tissue compartment model. 
The Ctiss,x indicates the tracer concentration in the respective compartment, Cpl denotes plasma 
concentration and the k’s the transfer coefficients of the tracer exchange between the compartments.  
 
The relation demonstrates that the extraction fraction depends on the properties of the 
endothelium with respect to the tracer (PS) as well as the perfusion (CBF). The higher the 
perfusion (CBF) the smaller the extraction, because the average time spent close to the capillary 
wall decreases. However, the mass transfer in general still increases with flow, as the decrease of 
EF is more than compensated for by the higher abundance of tracer (CBF in the term CBF x EF in 
equation 5). For tracers with very high permeability (P), the extraction fraction is virtually 
independent of perfusion and approaches one. In this case, K1 equals CBF according to equation 
(5). However, in accordance with the reasoning above, a way to reduce dependence of the 
delivery on CBF is to select tracers that have a low extraction fraction across the capillary wall, 
which depends on S and P.   
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Fitting of the model to measured data 
The signal obtained by radiotracer measurements consists of contributions from the capillary bed 
and from the different tissue compartments and cannot be assigned to a single specific 
compartment. The plasma concentration is known from the measurement of the input curve as 
stated above. The task now consists of finding a set of rate constants (k values) such that the 
modeled tracer concentration optimally matches the measured tracer concentration. To this end, 
transfer coefficients are varied until the sum of squared residuals becomes minimal. Such analysis 
of measurements requires appropriate software (Figure 4).  
  
Figure 4. Kinetic modeling user interface of PMOD (Mikolajczyk et al. 1998) a dedicated software for 
compartmental modeling of kinetic data 
 Using an appropriate software, a model curve (blue line) is fitted till to optimally match the measured tissue 
time activity curve (green symbols). The measured time course of tracer activity in plasma is shown in red 
(input curve). The resulting transfer coefficients from this procedure are indicated on the right (yellow box; in 
this example for a two-tissue compartment model (K1 – k4)). The random distribution of the residuals (bottom 
window) indicates that the chosen model explains the kinetics of the tracer adequately. 
 
It is common knowledge that more complex models better fit acquired data, but for compartment 
models this means that the number of transfer coefficients increases and may vary significantly 
without major changes in the resulting model curve. Under these circumstances, the transfer 
coefficients cannot be estimated reliably. A general rule in kinetic modeling states that models 
should be applied that predict the measurements with the least possible number of parameters. 
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Most often only simple models with one or two tissue compartments are applied and the question 
arises whether an additional tissue compartment improves the fit and should be considered. 
 
Analogy of the radiotracer method with a pipe system 
One of the goals of tracer methods is to evaluate mass fluxes in a biological system. Fluxes can 
mathematically be described as follows: 
 
ܨ௑   ൌ ݇௜  ൈ ܥ௑ (7) 
 
Here, FX denotes the mass flux of substance X through a biological system, CX is the concentration 
of substance X in the originating compartment and ki is a composite function of all factors 
determining the flux of the substance X through the system and is practically what we measure 
using radiotracer kinetics. The system can be compared to fluid flow in a pipe system with valves, 
where the flow is determined by the pressure at the entry (~ concentration of the substance CX) 
and the position of the valves (corresponding to ki). The aim of radiotracer methods is to determine 
factor ki – the position of the valves in the system. If ki is known and CX can be measured, the flux 
can be calculated easily from equation (7).  
In the next few sections, the most common radiotracer imaging methods will be introduced and 
detailed characteristics of every method are discussed. 
 
 
  
Radiotracer methods 
 
 
31 
 
Radiotracer methods for the measurement of brain metabolism 
Autoradiography 
This methodology was introduced more than fifty years ago and measures tissue concentrations of 
radiolabeled compounds in animals injected with the tracer. Concerning the work in the field of 
brain metabolism, particularly autoradiographic studies for the measurement of glucose utilization 
(Sokoloff et al. 1977) and cerebral blood flow (Landau et al. 1955; Sakurada et al. 1978) are widely 
used. 
 
Figure 5. Example of an 18F-fluorodeoxyglucose autoradiography of the rat’s brain 
The autoradiographic approach nicely shows the spatial distribution of radiotracers. In this example the 
elevated glucose utilization in the left somatosensory cortex during 2 Hz electrostimulation of the right 
infraorbital nerve is reflected by a clear increase of 18F-fluorodeoxyglucose uptake (uptake time: 45 minutes). 
10 µm thick brain slices were exposed to a phosphor imaging plate during 4 hours. The high spatial 
resolution provided by the autoradiographical method is evident if compared with Figure 8 (human brain PET 
study using 18F-fluorodeoxyglucose). 
 
In short, the procedure of an autoradiographic experiment can be described as follows: The 
radiochemical drug tracing the investigated biochemical process is injected intravenously. After an 
adequate uptake period, the animal is sacrificed and the brain is removed. The brain is cut in a 
R L 
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cryostat and the sections are exposed to X-ray films or phosphor imaging plates for the 
measurement of the radioactivity concentration in the tissue. The resulting autoradiographs provide 
a circumstantial representation of the relative radiotracer distribution in the tissue under study. 
Local tissue radioactivity concentrations are determined using a calibration curve obtained in 
previous calibration experiments with methylacrylate standards, which are exposed together with 
known tissue concentrations. The autoradiographical approach is the method of choice if a high 
spatial resolution is important as depicted in Figure 5.  
 
Figure 6. Metabolism of 2-deoxyglucose in comparison to native glucose 
Radiolabeled deoxyglucose (e.g. 18F-FDG, marked with an asterisk) is taken up into the cell via glucose 
transporters independent of blood flow and phosphorylated by the enzyme hexokinase similar to native 
glucose. But it is not further metabolized thereafter and trapped within cells. Intracellular accumulation of the 
radiolabeled deoxyglucose derivative is directly proportional to hexokinase activity or to the cellular glucose 
utilization.  
 
The main disadvantages of this technique are its invasiveness and the fact that only one time point 
in the evolution of the tracer distribution can be measured per animal, which obviously limits the 
applicability for investigations of tracer kinetics. To obtain time courses of a tracer’s enrichment in 
the tissue there is a need for sacrificing a large number of animals at different time points. For 
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accurate kinetic validation better real kinetic data is needed, which can be obtained by PET or beta 
probe studies (see below).  
Furthermore, the capability of the autoradiographic method to derive quantitative values critically 
depends on the kinetic behavior of the tracer. Only if the tracer gets trapped within the tissue and 
the trapping is not dependent on blood flow, one autoradiograph is sufficient to derive quantitative 
measures such as the assessment of glucose metabolism using radiolabeled 
deoxyglucose/fluorodeoxyglucose. The cells process these glucose-analogues in a similar fashion 
as native glucose only up to the phosphorylation step catalyzed by the enzyme hexokinase 
(Figure 6). Then, no further metabolization takes place and these compounds are trapped within 
the tissue making them suitable tracers for autoradiographic studies.  
In contrast, for tracers exhibiting strong washout kinetics single autoradiographs are not sufficient 
to obtain meaningful data. In Figure 7, this is illustrated with the example of radiolabeled acetate, a 
tracer for the estimation of astrocytic oxidative metabolism (reported in chapter l). Increases of 
oxidative metabolism in astrocytes are reflected by an increase in the washout of the tracer. This 
leads to a decreased tracer accumulation in the tissue after about >20 minutes as shown in Figure 
7. Between 15 and 20 minutes tracer accumulation is similar to that at rest conditions. Only at 
times shorter than 15 minutes an increased tracer uptake can be detected using autoradiographic 
studies, however, this increased tracer uptake could be explained by increased blood flow alone as 
modeling studies demonstrated. This example illustrates that knowing only single time points of a 
tracer’s tissue accumulation may not be sufficient to draw correct conclusions. Methods are 
needed that provide the possibility to measure the full time course of a tracer concentration. 
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Figure 7. Illustration of the difficulties arising in autoradiographic studies that use tracers exhibiting 
washout kinetics 
11C-acetate – a tracer for the estimation of astrocytic oxidative metabolism – displays an increased washout 
during infraorbital nerve stimulation (black line) compared to baseline (blue line). Red arrows illustrate tracer 
uptake as determined in autoradiographic studies performed at corresponding time points (e.g. after 25 
minutes a decrease in tracer uptake is observed despite the fact that oxidative metabolism increases in 
astrocytes. See main text for further details).  
 
 
Positron Emission Tomography 
The development of PET made it possible to extend the autoradiographic approach for measuring 
rates of biochemical processes non-invasively in humans (Phelps et al. 1975; Phelps et al. 1982; 
Phelps et al. 1986). Highly sensitive PET offers the possibility to assess regional brain function in a 
fully quantitative way and provides dynamic tomographic information (Figure 8). It allows the 
investigation of biochemical pathways or molecular targets with specific radiolabeled compounds. 
The continuing development of novel imaging probes labeled with a positron-emitting isotope (the 
most common used PET isotopes together with some of their physical characteristics are listed in 
Table 1) will further expand the range of PET imaging in the future. 
The principle of the method is based on the detection of the positron decay. The radiolabeled 
Radiotracer methods 
 
 
35 
 
compounds are introduced in the organism generally by intravenous injection. The radiotracer will 
distribute in the organism according to its delivery, uptake, metabolism and excretion 
characteristics. At any given time, some of the radioactive nuclides will decay by emission of a 
positron and a neutrino. The neutrino leaves the body without any further interaction. In contrast, 
the positron travels a short distance in the tissue while losing energy and finally annihilates with an 
electron leading to the conversion of the mass of the positron and the electron to electromagnetic 
energy. During this process two gamma rays are emitted at an angle of 180° with an energy of 511 
keV each, which escape the body and can be detected by the PET detector crystals. The PET 
scanner acquires these coincidence events on opposite sides of the crystal ring. The line on which 
such an annihilation reaction occurs is called line of response. By combining millions of such lines 
of response of many different angles, the data can be reconstructed into cross-section images 
using standardized image reconstruction algorithms. The distribution of counts in the resulting 
images reflects the concentration of the positron-emitting radiotracer in the tissue. To attain a 
linear relationship between the counts measured by PET and the tracer concentration in the tissue 
several corrections are necessary. 
 
Figure 8. PET study of a human brain using 18F-fluorodeoxyglucose 
On the left human brain PET slices are shown of a 18F-FDG study. The corresponding time activity curve of 
the cortex is plotted on the right. (1) visual cortex, (2) thalamus, (3) caudate nucleus; (4) putamen, (5) 
temporolateral cortex, (6) frontal cortex and (7) cerebellum. 
 
Besides correction for gamma ray attenuation by the tissue, images have to be corrected for 
scattered and random events detected in order to obtain images reflecting real tracer concentration 
in the field of view. Spatiel resolution of clinical human PET scanners is physically limited to about 
4 to 6 mm rendering its use in rodents nearly impossible. Recently dedicated small animal PET 
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scanners were introduced for experimental studies in the rodent which reach spatial resolutions 
down to 1 mm (Chatziioannou 2002; Hume and Myers 2002; Rowland and Cherry 2008; Weber 
and Bauer 2004). The advent of these high-resolution small animal PET systems may help to 
bridge the gap between animal and human studies. However, these systems suffer from various 
drawbacks as discussed below. 
 
Beta probe system 
The range of PET applications is continuously broadening by the current development of new 
radiotracers. However, new compounds require validation in laboratory animals before their use in 
humans. In earlier years, these validation experiments consisted in ex vivo measurements 
requiring the sacrifice of a large number of animals. The introduction of small animal PET systems 
facilitated the quantification of tracers over time in significantly less animals. However, these 
systems suffer from several drawbacks: 1.) they are expensive, 2.) have a low temporal resolution, 
3.) animals have to be immobilized by anesthesia which restricts neurophysiological investigations 
and 4.) fully quantitative experiments with the need for parallel measurement of the arterial input 
curve are difficult due to the geometry of the scanners. Furthermore, quantitative in vivo evaluation 
of new PET tracers for brain studies often requires only the measurement of the radioactivity 
concentration in a few brain structures and a tomograph is unnecessary. Therefore, recently 
introduced beta probe systems offer an elegant way to measure time courses of radiotracer 
enrichment in single tissue regions in rodents with high temporal resolution (Ginovart et al. 2004; 
Pain et al. 2000; Pain et al. 2002b; Weber et al. 2003). Until now they were mostly used in brain 
studies but obviously they could also be used in other body organs. The potential applications of 
this method are widespread. Examples are blocking and displacing experiments with receptor 
ligands (Galineau et al. 2006; Wyss et al. 2007), measurement of glucose metabolism using 18F-
fluorodeoxyglucose during different conditions ((Millet et al. 2004; Pain et al. 2002a); for an 
example see Figure 9) and blood flow measurements (Weber et al. 2003).  
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Figure 9. Beta probe study in the rodent brain 
Decay corrected time activity curves of 18F-FDG in tissue, whole blood, and plasma. Electrostimulation of the 
left infraorbital nerve led to an increased glucose utilization in the right primary somatosensory cortex as 
measured by beta probes placed in both hemispheres of a rat brain. The inset depicts the corresponding 
autoradiography of this animal performed at the end of the kinetic measurement (the green filled circle marks 
the stimulated S1). S1 = primary somatosensory cortex.   
 
Compared to animal PET systems, beta probe systems are less expensive, demonstrate a higher 
temporal resolution and can potentially be performed in the awake animal (see Chapter lll). 
Currently, available beta probes consist of a scintillating crystal (1 mm in length and 0.25 to 1 mm 
in diameter), which is attached to an optic fiber. Due to the limited range of β+ particles within 
tissue, only β+ particles from a defined sphere around the tip of the probe excite the crystal (Pain 
et al. 2002b). β+ particles originating from distances beyond the maximum range in biological 
tissues (see Table 1) will be stopped in the tissue before they can interact with the crystal and will 
not be detected. The photons produced in the scintillating crystal are measured using 
photomultiplier tubes and counting electronics yielding a measure of the radioactivity 
concentration.  
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Table 1. Physical properties of the most commonly used PET isotopes
Radionuclide Half‐l ife  Range in tissue β+ maximum energy FWHMb
(min) (mm) (keV) (mm)
F‐18 109.8 2.4 640 0.6
C‐11 20.4 4.1 960 0.9
N‐13 9.96 5.4 1720 1.0
O‐15 2.07 8.2 1190 1.6
FWHM = full  width at half maximum
bFundamenta l  PET resolution l imit calculated for a  20‐cm‐diameter scanner and 
infini tely thin detectors  (Levin and Hoffmann, 1999) 
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Comparison of radiotracer techniques with other in vivo methodologies 
common used for the study of brain metabolism 
 
The following section highlights some aspects of two other in vivo methods that have been used in 
the field of brain metabolism research for several years to investigate the organisation of brain 
energy metabolism and its compartmentalization. Among other techniques, which are not 
discussed in this introduction, nuclear magnetic resonance spectroscopy and microdialysis studies 
have played a major role in advancing our understanding of human brain metabolism. Some 
general aspects are introduced and put into context with radiotracer methods. 
 
Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance spectroscopy (MRS) has been introduced in the 1980s for the non-
invasive study of human brain metabolism (Prichard and Shulman 1986). The most common MRS 
approach for brain metabolic studies relies on the infusion of stable 13C- enriched substrates (e.g. 
13C-glucose, -acetate, -lactate, ketone bodies etc. (Escartin et al. 2006)). 13C has a low natural 
abundance of ~1.1% which makes the measurement of the isotopic incorporation into brain 
metabolites possible by way of i.v. infusion of 13C enriched substrates. The quantification of energy 
metabolism by MRS is mainly based on the detection of 13C accumulation within metabolites of the 
two large cerebral pools (neuronal pool of glutamate / astrocytic pool of glutamine). MRS has the 
unique property that it can specifically identify different molecules and the atomic position of the 
13C label. In contrast to radiotracer techniques that measure a single time activity curve of all 
radiolabeled substrates in the region of interest, MRS provides several 13C time courses, which is 
sufficient to derive metabolic fluxes from all major pathways labeled by the infused 13C compound. 
The 13C enrichment pattern of amino acids in the brain reflects the compartmentation of brain 
energy metabolism (Bouzier-Sore et al. 2003a). 
The fine biochemical probing comes at the expense of a low intrinsic sensitivity. The detection of 
trace amounts of the label is not possible. Another consequence of the low intrinsic sensitivity is 
the need to perform MRS in large brain voxels at least one order of magnitude larger than in
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radiotracer techniques (Escartin et al. 2006). Therefore, MRS is not yet really suitable for exploring 
focal brain activation. However, promising developments are under way that provide high 
resolution MRS. As is the case for presently available radiotracer techniques, MRS is currently 
unable to directly resolve the controversy about the existence of the proposed lactate shuttle 
between neurons and astrocytes (Magistretti et al. 1999) because a clear compartmentation of 
lactate in the brain does not exist. 
 
Microdialysis  
Microdialysis studies have been used to measure both levels of neurotransmitters and of energy 
substrates (Obrenovitch and Zilkha 2001). After the insertion of a specific probe into an area of 
interest of the living brain, the measurements allow monitoring changes in the composition of the 
extracellular fluid with enzyme-based dialysate analyses or the detection of CO2 recovery after 
infusion of radiolabeled substrates. Especially the latter methodology has been used regularly for 
brain metabolism-related studies. Via microdialysis probes, radiolabeled compounds are infused to 
pulse label the respective endogeneous substrates. The resulting radiolabeled CO2 formed by the 
oxidative metabolism is then measured in the eluate from the probe (Huang et al. 1993; Zielke et 
al. 1998; Zielke et al. 2007) yielding a direct measure of oxidative metabolism. However, absolute 
rates of oxidative metabolism cannot be determined by this methodology. Furthermore, resulting 
CO2 levels are usually determined in several minute dialysate fractions largely limiting the temporal 
resolution. In addition to the low temporal resolution, the method is also hampered by limited 
spatial resolution due to simultaneous probing of a large number of brain cells.  Microdialysis 
studies report only bulk changes in extracellular metabolites with severely limited temporal and 
spatial resolution. Rapid and localized events may be averaged out. The strength of the method is 
the possibility to be performed also in the freely-moving animal (Obrenovitch and Zilkha 2001). 
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Aims of the project 
 
The concept of compartmentalization of cerebral metabolism has existed for about 40 years mainly 
based on experiments studying the occurrence of label in brain metabolites after the injection of 
various radiolabeled compounds (Cremer 1970; Minchin and Beart 1975a; Minchin and Beart 
1975b; Van den Berg et al. 1969). In the following years there were several MRS-based studies 
that evaluated different aspects of the compartmentalization such as the glutamate-glutamine cycle 
(Aureli et al. 1997; Serres et al. 2008; Shen et al. 1999), distinct TCA cycle activities in neurons 
and astrocytes (Lebon et al. 2002; Tyson et al. 2003) and their close coupling to different states of 
brain activity (Sibson et al. 1998). 
However, low temporal and spatial resolution, low sensitivity, and the inability of absolute 
quantification limit the abovementioned methodologies, giving rise to the development of 
complementary methods for the study of brain energy metabolism. Approaches that allow the in 
vivo estimation of specific process rates in distinct cerebral metabolic compartments can extend 
the knowledge about the compartmental interplay and the contribution of single metabolic 
compartments in the working brain. 
In general, the main objectives of the present work were on the one hand to evaluate radiotracers 
for their use in brain studies, on the other hand to improve the applied methodology.  
 
(l) In a first part 1-11C-acetate, previously used for the measurement of oxygen consumption in the 
heart (Armbrecht et al. 1990; Buck et al. 1991; Lindner et al. 2006), was investigated with regard to 
its potential use in brain to study oxidative metabolism in astrocytes. Based on the hypothesis that 
label washout after injection of the radiolabeled astrocyte-specific substrate acetate reflects 
oxygen consumption in astrocytic cells, experiments using different interventions were performed. 
The results demonstrate the potential of the approach.  
 
(ll) A second part of the project focused on the neuronal compartment. The newly synthesized 
lactic acid enantiomer (Drandarov et al. 2006) 1-11C-L-lactate was tested. Numerous studies 
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demonstrated that lactate constitutes an excellent oxidative substrate for neurons (for review see 
(Pellerin 2003)) and that lactate is preferentially consumed by neurons (Bouzier-Sore et al. 2006). 
The current study is motivated by these results and based on the hypothesis that changes in 
kinetics of the radiolabeled lactic acid may reflect changes in neuronal oxidative metabolism. The 
following specific issues were addressed: 
 1.) Characterization of 1-11C-L-lactate kinetic properties in brain tissue, such as first pass 
 extraction fraction.  
 2.) Investigation of possible changes in kinetic behavior during increased neuronal activity. 
 3.) Explanation of these potential changes according to the actual knowledge of brain 
 metabolism.       
 
(lll) Finally, the last objective of the work was to develop and evaluate a novel surface probe. The 
current intracortical probes suffer from several drawbacks: the need for insertion into the tissue 
leads to potential tissue damage, the probes exhibit limited detection sensitivity, and it is difficult to 
use the system in the non-anesthetized animal. A more sensitive surface probe that can be applied 
through the bone has the potential to be used in awake animals.  
 
A better understanding of the kinetics of lactate and acetate utilization in the brain in vivo may 
increase our knowledge about the compartmentalization of brain energy metabolism. The 
possibility to study neuronal and astrocytic oxidative metabolism in vivo in an independent, 
quantitative, and separate manner is a promising approach to improve our understanding of the 
interplay between the two major cerebral cell types.  
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Abstract 
 
The purpose of this study was to investigate astrocytic oxidative metabolism using 1-11C-acetate. 
1-11C-acetate kinetics were evaluated in the rat somatosensory cortex using a beta scintillator 
during different manipulations (test-retest, infraorbital nerve stimulation and administration of 
acetazolamide or dichloroacetate). In humans a visual activation paradigm was used and kinetics 
were measured with positron emission tomography. Data were analyzed using a one-tissue 
compartment model. The following features supported the hypothesis that washout of radiolabel 
(k2) is due to 11C-CO2 and therefore related to oxygen consumption (CMRO2): 1) the onset of 11C 
washout was delayed; 2) k2 was not affected by acetazolamide-induced blood flow increase; 3) k2 
demonstrated a significant increase during stimulation in rats (from 0.014 ± 0.007 to 0.027 ± 0.006 
min-1) and humans (from 0.016 ± 0.010 to 0.026 ± 0.006min-1) and 4) dichloroacetate led to a 
substantial decrease of k2. In the test-retest experiments K1 and k2 were very stable.  
In summary, 1-11C-acetate seems a promising tracer to investigate astrocytic oxidative metabolism 
in vivo. If the washout rate is indeed representing the production of 11C-CO2, then its increase 
during stimulation would point to a substantially higher astrocytic oxidative metabolism during brain 
activation. However, the quantitative relationship between k2 and CMRO2 needs to be determined 
in future experiments. 
 
Key words: 1-11C-acetate, astrocytes, beta scintillator, oxidative metabolism, positron emission 
tomography, washout 
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Introduction 
 
There is increasing evidence that astrocytes and neurons constitute a tightly coupled metabolic 
unit. Already early studies of brain metabolism using 14C-labeled precursors such as glucose or 
acetate led to the concept of two distinct tricarboxylic acid (TCA) cycle compartments, i.e. two 
separate pools for glutamate and glutamine (Berl and Frigyesi 1969; Cremer 1970; Minchin and 
Beart 1975a; Van den Berg et al. 1969). Later histochemical work on the restricted localization of 
glutamine synthetase to glial cells (Martinez-Hernandez et al. 1977; Norenberg and Martinez-
Hernandez 1979) further supported the idea on the glial and neuronal site of these distinct pools. 
Simplification of these data has sometimes led to the wrong assumption that the oxidative activity 
of astrocytes is negligible. However, studies using mainly NMR spectroscopy have suggested that 
astrocytic energy metabolism indeed contains a substantial oxidative component which may 
account for up to 30% of total oxidative metabolism in brain under resting conditions (for review 
see (Hertz and Kala 2007; Hertz et al. 2007; Hyder et al. 2006). Recent transcriptome analysis has 
revealed a pattern of gene expression in astrocytes consistent with a significant oxidative activity 
(Lovatt et al. 2007). 
Another question is how astrocytic metabolism behaves during activation. A recent study using ex 
vivo autoradiography with 14C labeled acetate at the carbon 2 position suggested that astrocytic 
oxidative metabolism increases with brain activity (Cruz et al. 2005). Labeled acetate is a 
promising candidate to investigate astrocytic oxidative metabolism in vivo because it is selectively 
taken up and metabolized by astrocytes (Hassel et al. 1992; Muir et al. 1986; Waniewski and 
Martin 1998). Earlier studies in the heart muscle have further revealed that quantitative measures 
for oxygen consumption can be derived from the washout rate of label after injection of 
radiolabeled acetate (Buck et al. 1991). Acetate can be labeled in the 1- or 2-carbon position. 
Whole body studies using 13C labeled acetate demonstrated that labeled CO2 is produced during 
the second or third turn in the TCA cycle, depending on whether 1-13C-acetate or 2-13C-acetate 
was used (Wolfe and Jahoor 1990). However, these results reflect whole body metabolism, brain-
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specific reactions cannot be directly derived from them. In brain, with 1- and 2-labeled acetate 
there was substantial labeling of amino acids, such as glutamate, glutamine and aspartate and 
further TCA cycle intermediates as shown in older and more recent literature (Badar-Goffer et al. 
1990; Berl and Frigyesi 1969; Lebon et al. 2002; Tyce et al. 1981; Tyson et al. 2003; Van den Berg 
et al. 1969; Van den Berg and Ronda 1976). However, the static measurement of metabolites at 
single time points yields only limited information on astrocytic oxidative metabolism.  
In this study we applied 1-11C-acetate and dynamic measurements to investigate astrocytic 
oxidative metabolism. Specific questions were: 1) what is the extraction fraction of the tracer, 2) 
what is the kinetic behavior at baseline and during stimulation and 3) how does dichloroacetate, an 
agent that increases the production of acetyl-CoA from pyruvate in the cell, change the kinetics of 
1-11C-acetate and 4) is the loss of radiolabel dependent on blood flow. Studies were performed in 
rats and humans. In rats data were acquired using a beta scintillator, in humans we applied 
positron emission tomography.  
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Material and Methods 
 
Automated radiosynthesis of sodium 1-11C-acetate   
11C-CO2 was produced by the 14N(p,α)11C nuclear reaction using a nitrogen gas (N2/0.5%O2) 
target. 11C-CO2 was bubbled at room temperature in a mixture of methylmagnesium bromide (3M 
solution in diethyl ether; Fluka, 70 μl, 0.21 mmol) and dry diethyl ether (3 ml) placed in the reactor, 
where the chemical trapping of the 11C-CO2 by C-carboxylation of the Grignard reagent takes place 
instantly. After delivery (10 min) the reaction was quenched by automated addition of nearly 
equimolar amount of acid (1 ml 0.2M aqueous HCl, 0.2 mmol HCl) and the diethyl ether from the 
bilayer mixture was removed by evaporation in a stream of nitrogen (100 ml/min) for about 10 min. 
The residual water solution of 1-11C-acetic acid was automatically drawn into the loop of the 
preparative chromatograph (Merck-Hitachi chromatograph equipped with L-4000A UV detector at 
254 nm, isocratic pump L-6000A, 5 ml loop, and radiation detector Radiation Monitor, Eberline 
Instrument Corporation, Santa Fe, New Mexico), injected into a semipreparative reversed phase 
column (Polymerx, 10 µm, 250 x 10 mm, Phenomenex) and eluted with a mixture of sterile salt 
physiologic solution as the mobile phase. The fraction corresponding to the 1-11C-acetic acid (tR = 
7 min) was collected  to give up to 10 GBq activity of no-carrier-added sodium 1-11C-acetate with 
over 99% radiochemical purity and specific activity of about 400 GBq/μmol at the end of the 
synthesis in 10 ml sterile isotonic, buffered at physiological pH solution. The radiolabeling was 
performed in a lead shielded cell using a computer assisted homemade automatic apparatus 
controlled by LabVIEW software (National Instruments) via Modulink and RS232 interfaces.  
 
Radiotracer experiments 
Experiments were performed in animals using the beta scintillator and in humans using positron 
emission tomography (PET). All animal experiments were approved by the local veterinary 
authorities and were carried out in accordance with their guidelines. The experiments were 
performed by licensed investigators. The animals were kept in cages in a ventilated cabinet with 
standardized conditions of light (night/day-cycle 12h/12h) and temperature and free access to food
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and water. Before the experiment the animals were fasted overnight. 29 Sprague-Dawley rats (5 
for the extraction fraction determination, 24 for the different experimental paradigms (for details 
see below) weighing 310 ± 41 g (mean ± standard deviation) were included in the study. 
The human study population was composed of six healthy male volunteers aged between 24 and 
36 yrs without any known neurological impairments. All subjects were studied at the University 
Hospital Zurich. Informed written consent was obtained from all subjects before the beginning of 
the experiment. The protocol was approved by the local Ethics committee. 
MR scanning was performed on each subject (Twin Speed, GE Medical systems, Milwaukee, 
USA) to rule out any cerebral pathologies and for anatomical coregistration of the PET scan.  
 
Animal preparation 
Surgery was performed under isoflurane anesthesia and involved the placement of an 
arteriovenous (a-v) shunt from the right femoral artery to the right femoral vein, tracheotomy for 
mechanical ventilation and exposition of the skull with subsequent thinning of the bone above the 
primary somatosensory cortex using a dental drill. The actual experiment was then performed 
under urethane anesthesia (1400 mg/kg i.p.). The a-v shunt was used for the injection of the 
tracer, for collecting blood samples for metabolite analysis, for the monitoring of arterial blood 
pressure and for the continuous measurement of total arterial 11C activity. For the latter purpose, 
the shunt was run through a coincidence counter (GE Medical Systems) that stored the whole 
blood radioactivity concentration at 1-second intervals. The online arterial sampling procedure is 
described in detail elsewhere (Weber et al. 2002a).  
 
Beta scintillator  
The beta scintillator (Swisstrace, Zurich, Switzerland) has been described in detail earlier (Weber 
et al. 2003; Wyss et al. 2007). In short, it consists of a scintillation tip (Bicron, BF12, Newbury, OH, 
USA) with a length of 1 mm and a diameter of 0.25 mm attached to a high numerical aperture 
glass fiber. The scintillator was made light-tight by applying a uniform coating of silver particles. 
The scintillations were measured using a photomultiplier tube and counting electronics (Perkin 
Elmer, Massachusetts, USA). The limited range of beta particles within biological tissues leads to a 
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limited detection volume centered around the scintillating tip of the probe. Monte Carlo simulations 
demonstrated that for C-11 the distance required to detect 90 % of the beta particles around the 
probe is 2.0 mm (Pain et al. 2002b). The sensitivity of the used beta scintillator was in the range of 
0.036 to 0.047 cps/kBq/cc. 
The scintillator was inserted into the cortex using a stereotactic frame (David Kopf Instruments, 
Tujunga, CA, USA). At the insertion point, which was about (according to Bregma) 1 mm posterior 
and 5 mm lateral, the thinned bone was removed and the dura was carefully incised. The 
scintillator tip was lowered 1.4 mm below the dura. In the stimulation experiments, the correct 
position was verified by Laser Doppler flowmetry (Periflux System 5000, Perimed AB, Järfälla, 
Sweden). This position was adjusted to avoid large superficial blood vessels. Only one scintillator 
penetration was performed per animal. The count rate was stored on a personal computer using a 
bin width of 1 second yielding tissue time activity curves. 
 
Positron emission tomography 
All subjects were scanned on a whole-body Positron emission tomography/ Computertomography-
scanner (Discovery ST-RX; GE Medical Systems, Waukesha, USA). This is a scanner with an 
axial field of view of 14.6 cm and a reconstructed in-plane resolution of about 7 mm. Before the 
positioning of the subjects in the scanner, a radial artery was cannulated for timed arterial blood 
sampling. An additional catheter for administration of the radiotracers was placed in the 
contralateral antecubital vein. At the beginning of each study, a low dose computer tomogram for 
attenuation correction was performed. 
 
Experimental protocols 
a) Cerebral blood flow measurements using H215O - First pass extraction fraction 
The first pass extraction fraction (EF) of 1-11C-acetate at baseline was determined according to the 
relationship EF = K1/CBF, where K1 is the transport parameter of the one-tissue compartment 
model and CBF is cerebral blood flow. CBF was determined in 5 animals using 15O labeled water 
injected prior to measurement of 1-11C-acetate kinetics. In the human study CBF was measured in 
all subjects 10 minutes before the 1-11C-acetate injections. The visual stimulation was interrupted 
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between CBF and acetate measurements. Approximately 300 MBq H215O were injected 
intravenously using an automatic injection device. Following the arrival of the bolus in the brain, the 
acquisition of a series of 18 frames (10 s each frame) was started.  
 
b) Measurements of 1-11C-acetate kinetics during different conditions 
In the animal experiments two injections spaced 30 minutes apart were performed. Data were 
acquired for 20 minutes after the injection (slow injection over a period of 30 seconds) of 230-260 
MBq (diluted in 0.5 ml) of radiotracer. This part of the study included 24 animals, which were 
distributed among the following experimental subgroups: l) in this group the baseline was followed 
by electrostimulation (bas-stim); ll) the order was reversed (stim-bas). Groups I) and II) were 
examined with respect to a potential order effect. lll) To evaluate the reproducibility two 
consecutive baseline measurements were performed (bas-bas). IV) In four animals the effect of 
acetazolamide (Diamox®, 66 mg/kg), a carbonic anhydrase inhibitor increasing CBF but not 
oxygen consumption (CMRO2; (Okazawa et al. 2001)), on the kinetics of 1-11C-acetate was 
examined. After 20 minutes of baseline acquisition, acetazolamide was intravenously injected over 
one minute. Ten minutes later the same amount of 1-11C-acetate was injected for the second time. 
In a last group (V) the effect of dichloroacetate was investigated. Four hours after the injection of 
dichloroacetate (50 mg/kg, Sigma-Aldrich Prod. No. 347795) a baseline study was followed by 
electrostimulation (dichloroacetate challenge). Dichloroacetate was dissolved in physiological 
saline and was adjusted to pH 7.4. 
To activate the whisker-to-barrel pathway the infraorbital branch of the trigeminal nerve was 
electrically stimulated with two stainless steel electrodes. The cathode was inserted through the 
infraorbital hiatus and the anode was positioned in the masticatory muscle on the ipsilateral side. 
The current was adjusted to 2 mA and 2 Hz stimulation frequency was chosen because previous 
measurements using 18F-fluorodeoxyglucose-autoradiographies demonstrated this frequency to be 
optimal eliciting a maximal increase in glucose consumption of 70 to 80 % (unpublished data). The 
stimulation started 30 seconds before the tracer injections. To check the effectivity of the applied 
stimulation and the effect of acetazolamide in group IV) animals, a Laser Doppler flowmetry probe 
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was fixed just above the primary somatosensory cortex to follow regional cerebral blood flow 
(rCBF) changes.  
In humans PET was performed under baseline conditions with eyes closed and during visual 
stimulation using different video clips presented on a screen (Charlie’s angels & Rolling stones). In 
three subjects the baseline examinations were preceding the stimulation studies and in the other 
three subjects the order was reversed to rule out any order effect. The visual stimulation was 
started 20 seconds before scan start and continued during complete PET acquisition. After the 
intravenous injection of 250 MBq 1-11C-acetate administered as a slow bolus over approximately 
60 s data were recorded for 20 minutes (25 frames: 6 x 20 s, 3 x 40 s and 16 x 60 s).  
Time activity curves were derived from volumes of interest defined on three consecutive slices on 
the anatomical MR scans and subsequently transferred to the PET data. Volumes of interest were 
drawn in the visual cortex as the target region and in the frontal cortex and cerebellum as 
references.  
 
Statistics 
The Wilcoxon Signed Rank test for dependent samples was used to evaluate differences between 
within-subject conditions and the Mann Whitney U test was used for group differences. The 
criterion for significance was set at p < 0.05. Values are expressed as mean ± sd. 
 
Data acquisition and analysis 
 
The details are described in the appendix. 
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Results 
 
A. Animal studies 
Metabolites of 1- 11C-acetate in the blood  
HPLC identified 11C-CO2 as the only metabolite in blood. The time course of the fraction of 
authentic 11C-acetate in arterial plasma is demonstrated in Figure 1. The pH and arterial blood 
gases were all in the physiological range (pH = 7.35 – 7.45; pCO2 = 35 – 45 mmHg; pO2 = 70 – 
100 mmHg).  
Plasma lactate levels were also determined as lactate competes with acetate for the uptake into 
brain.  They ranged between 1.4 and 2.1 mmol/l. However, no relationship between plasma lactate 
levels and changes in the kinetics of 1-11C-acetate could be found. Only in group V 
(dichloroacetate challenge) there was a statistically significant difference in plasma levels between 
the two different modalities (see below).  
 
First pass extraction fraction.  
CBF was measured in 5 baseline experiments and was 56 ± 16 ml/min/100g. The first pass 
extraction fraction of 1-11C-acetate calculated in these experiments was 18 ± 5 %. 
 
Reproducibility of the 1-11C-acetate measurements  
The reproducibility of the time activity curves and of the parameters K1 and k2 is demonstrated in 
the top graphs of Figure 2 and 3. In contrast to trigeminal nerve stimulation, the tissue time activity 
curves in the 2 sequential baseline experiments look identical. The difference of the mean K1 
(K1experiment2 - K1experiment1 ) was –0.001, and for k2 the difference was 0.002 min-1. 
 
1-11C-acetate kinetics during infraorbital nerve stimulation 
The electrical infraorbital nerve stimulation increased the washout of 1-11C-acetate as shown in the 
middle graph of Figure 2. The order of the experiments (baseline-stimulation or stimulation-
baseline) had no significant effect on the changes of the kinetic parameters (Figure 3C and 3D). 
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Therefore the two groups l) and ll) (bas-stim and stim-bas) were pooled. During stimulation, k2 
increased by 93 % from 0.014 ± 0.007 to 0.027 ± 0.006 min-1 (p < 0.01) in the primary 
somatosensory cortex. In parallel, K1 increased from 0.080 ± 0.015 at baseline to 0.095 ± 0.017 
ml/min/ml tissue (p < 0.01). The efficacy of the stimulation was confirmed by the increase of the 
laser Doppler flowmetry signal by 20 – 25 % (data not shown). 
To check for a delayed onset of the radioactivity washout, the first 5 minutes of data were refitted 
with only k2 as a free parameter. In this data set k2 decreased from 0.014.± 0.007 to 0.001 ± 0.002 
min-1 in the baseline experiments and from 0.027 ± 0.006 to 0.003 ± 0.004 min-1 in the stimulation 
experiments. An example of a 5 minute fit is illustrated at the bottom of Figure 2. The low k2 of 
0.001 fits the initial data well, then the washout is clearly increased.  
 
Effect of acetazolamide on k2 
In the 4 experiments k2 was 0.016 ± 0.002 min at baseline and 0.016 ± 0.002 min-1 10 minutes 
following acetazolamide injection. Laser Doppler flowmetry showed a signal increase of 61.1 ± 8.1 
%. 
 
Effect of dichloroacetate on k2 during baseline and stimulation  
Dichloroacetate pretreatment lowered arterial plasma lactate from 1.5 ± 0.1 to 1.25 ± 0.2 mmol/l 
(mean ± sd; p < 0.05) but exerted no change of arterial blood gases which stayed in the 
physiological range. Four hours after intravenous dichloroacetate administration, k2 was lower at 
baseline and during stimulation, compared to the experiments without dichloroacetate. At baseline 
the values were on average 36% lower (0.009 ± 0.002 compared to 0.014 ± 0.007 min-1), however, 
this difference failed to reach significance (n = 5; p = 0.15). During stimulation k2 was 26% lower (n 
= 5; p < 0.05) than in the experiments without administration of dichloroacetate (0.020 ± 0.004 
compared to 0.027 ± 0.006 min-1). There was still a significant 122 % increase of k2 from baseline 
to electrostimulation (from 0.009 ± 0.002 to 0.020 ± 0.004; n = 5; p < 0.05; Figure 3E) 
 
Relationship of the tissue activity and changes of the washout rate k2 
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This relationship is a measure of the parameter identifiability. A larger change of the tissue activity 
with a unit change of k2 is associated with a better parameter identifiability. The sensitivity analysis 
demonstrated that at 20 minutes, a 10 percent change in k2 led to a 2.1 percent change in tissue 
activity at baseline (k2 = 0.014 min-1) and to a 3.8 percent change during stimulation (k2  = 0.027 
min-1). Furthermore, the activity change in tissue was linear in the investigated range 0 – 30 % k2 
change.  
 
 
B. Human studies 
1-11C-acetate kinetics present the same characteristics as in animal studies 
In all subjects the blood gas parameters were always in the physiological range (pH = 7.35 – 7.45; 
pCO2 = 35 – 45 mmHg; pO2 = 70 – 100 mmHg). An illustration of the effect of the visual activation 
on the kinetic of 1-11C-acetate is demonstrated in Figure 4 and the quantitative values are shown 
in Figure 5. The calculated EF of 1-11C-acetate in visual cortex was 19 ± 4 % at baseline and 13 ± 
3 % during stimulation. The visual stimulation increased mean CBF in visual cortex by 64 % (p < 
0.05). In the control regions ‘cerebellum’ and ‘frontal cortex’ no significant change of the CBF was 
noticed. In visual cortex mean K1 and k2 values of 1-11C-acetate were 11 % and 62 % (p < 0.05 for 
both) higher during stimulation as shown in Figures 5F and 5I. No significant changes of K1 or k2 
were noted in frontal cortex and cerebellum. However, in frontal cortex K1 and k2 data are 
somewhat distorted by a single subject which showed a decrease of the values in this region in 
response to visual stimulation. 
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Discussion 
 
It was previously suggested that the astrocyte-specific substrate acetate allows to measure 
metabolism in human brains in vivo (Hosoi et al. 2004; Muir et al. 1986). However, to our 
knowledge this is the first study using label clearance from brain after 1-11C-acetate administration 
for the investigation of astrocytic oxidative metabolism in vivo. Labeled acetate was already used 
in various studies to illuminate certain aspects of astrocytic metabolism. Some groups used 
autoradiographical determination of 14C-acetate uptake (Cruz et al. 2005; Muir et al. 1986), other 
groups measured the metabolic fate of acetate by measuring the appearance of labeled 
compounds as the label travelled through the TCA cycle (e,g, (Badar-Goffer et al. 1990; Berl and 
Frigyesi 1969; Lebon et al. 2002; Van den Berg and Ronda 1976)). 
Our study demonstrates for the first time changes of 1-11C-acetate kinetics during stimulation in 
vivo which are thought to be correlated with changes of astrocytic oxidative metabolism. While total 
cerebral CMRO2 can be successfully measured in vivo using PET and inhaled 15O2 (Mintun et al. 
1984; Yee et al. 2006), a direct in vivo measurement of CMRO2 in astrocytes alone is not available.  
 
K1 and extraction fraction 
Compared to the heart where 1-11C-acetate is almost 100% extracted, the cerebral extraction 
fraction is about 5-fold lower. Nevertheless, brain uptake is large enough to allow quantification. 
One consequence of the lower extraction fraction is the blunted increase of K1 compared to CBF 
during stimulation. In the human study K1 increased 11 % compared to a 64 % increase in CBF 
(visual cortex).  
 
Quantitative relationship between k2 and astrocytic CMRO2  
In the following discussion about the meaning of the rate constant k2 we provide arguments that k2 
may be strongly related to CMRO2. However, it is clear that a direct proof is not given and would 
be difficult to establish as there is actually no data available to prove this conclusion directly. One 
major reason is that a direct measurement of astrocytic CMRO2 is yet impossible in vivo.  
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We hypothesize that k2 is directly related to CMRO2 in the astrocytes as has been demonstrated in 
the heart for the myocytes (Buck et al. 1991). Prerequisites for this hypothesis are a) the washout 
of radioactivity from the volume of interest is indeed due to the loss of 11C-CO2 and b) the rate 
limiting step determining k2 is the production of 11C-CO2 and not its removal. 
 
Prerequisite a) 
There seems to be no doubt that at least part of the radioactivity loss is due to 11C-CO2, since the 
production of labeled CO2 from exogenous 1-14C-acetate has been proven in astrocyte cultures 
(Waniewski and Martin 1998). However, a quantitative proof of prerequisite a) would be difficult. 
One theoretical possibility would be the measurement of the arterio-venous (a-v) difference of 11C-
CO2. However, a first order estimation of this difference demonstrates that it would be in the order 
of 4 % of the total blood counts. The conclusive demonstration of such a small difference would 
require a prohibitively large amount of animals.  
 
Prerequisite b)  
It is well known that CO2 diffuses practically freely across the blood brain barrier (Paulson 2002). It 
could therefore theoretically be possible that the removal of CO2 by the blood is a limiting factor for 
the washout of CO2. However, the lack of a change of k2 following the acetazolamide-induced 
blood flow increases demonstrates that the removal of the radioactivity from the volume of interest 
is not a limiting factor.   
Other arguments which point at a strong relationship between k2 and astrocytic CMRO2 are: 1) the 
increase of k2 during stimulation, 2) the delay of the onset of the label washout and the decrease of 
the K1/k2 ratio during stimulation 3) the behavior of k2 under dichloroacetate and 4) reasonable 
values of astrocytic CMRO2 can be obtained by applying the calibration established in the dog 
heart.  
 
Changes of k2 during increased brain activity 
Parameter k2 significantly increased during stimulation. In the animal study, k2 almost doubled from 
baseline to infraorbital nerve stimulation, indicating a substantial increase in oxygen consumption.
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In the human study the increase in the visual cortex was 63 %. Although not significant there also 
seemed to be a trend towards higher values in cerebellum and frontal cortex. In fact, omitting the 
subject with a lower value during stimulation, the increase became significant, not surprising 
considering the connectivity in the brain.  
 
Delay of the washout onset and the decrease of the K1/k2 ratio during stimulation 
Another result pointing at 11C-CO2 as the washout agent is the delay of the washout onset (bottom 
graph of Figure 2). Such a delay for the appearance of labeled CO2 was demonstrated by 
Waniewski and Martin in cultured astrocytes and is explained by the fact that labeled CO2 is only 
produced in the second turn of the label in the TCA cycle (Waniewski and Martin 1998). If the loss 
of label was substantially due to backdiffusion of labeled acetate, one would not expect a delay. 
Furthermore, if backdiffusion of labeled acetate was the main factor determining k2, one would 
expect the same effect of stimulation on K1 and k2, i.e. the ratio K1/k2 would remain constant. 
However, the data demonstrate a markedly lower ratio during stimulation. In the anesthetized rat 
studies, the mean ratio dropped 44 % (p=0.08), in the studies with dichloroacetate the decrease 
was 53 % (p=0.001) and in the human visual cortex the ratio dropped 44 % (p=0.048). This 
behavior suggests that the labeled compounds entering and leaving the brain tissue are different. 
The mentioned points are all consistent with the hypothesis that the washed out compound is 
indeed 11C-CO2. However, we cannot completely exclude that some label loss is due to release of 
other labeled substrates, particularly due to efflux of glutamine, which is quickly labeled after 
injection of radiolabeled acetate (Cremer 1970). Despite the fact that the blood brain barrier is 
closed for the passage of glutamate and glutamine from blood to brain the reverse direction seems 
possible. Glutamine is taken up by endothelial cells and intracellularly converted by the enzyme 
glutaminase to glutamate. When the glutamate concentration within endothelial exceeds the one in 
plasma net transport of glutamate takes place through facilitative transporters (Hawkins et al. 
2006). The high number of steps involved in this process and the fact that normal plasma 
concentration of glutamate is about 10 times higher than glutamate concentration in the 
extracellular fluid of the brain (Hawkins et al. 2006) indicate that this process is slow and probably 
not of relevance during our acquisition period of 20 minutes. 
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Pharmacological interventions using dichloroacetate and acetazolamide. 
Also the dichloroacetate experiments are consistent with the hypothesis that k2 is related to 
CMRO2. This compound activates pyruvate dehydrogenase (Abemayor et al. 1984) by inhibiting its 
phosphorylation by the PDH kinase (Whitehouse et al. 1974). As a consequence more pyruvate is 
converted to acetyl-CoA and less to lactate and the concentration of acetyl-CoA is expected to 
increase. If the rate constants in the following chain of acetyl-CoA oxidation, which are expected to 
be related to k2, remained the same, the rate of the acetyl-CoA metabolism would increase and 
with it most likely CMRO2. However, since the energetic demand is unchanged there is no reason 
why CMRO2 should increase. Consequently one would expect a decrease in k2 and this is exactly 
what was observed, at baseline as well as during stimulation. A good candidate for regulation at 
this stage is citrate synthase which condenses acetyl-CoA and oxaloacetate into citrate. It has 
been documented that this enzyme is inhibited by increased concentrations of acetyl-CoA (Bayer 
et al. 1981). This inhibition could be a major reason for the observed decrease of k2 following 
dichloroacetate. Furthermore, the suggested increase of the cold acetyl-CoA concentration under 
dichloroacetate is itself indirect evidence for the ability of astrocytes to completely oxidize glucose, 
as is the work by Lovatt et al. which confirmed significantly higher relative expression of almost all 
TCA cycles enzymes in freshly isolated astrocytes than neurons and showed that the oxidative 
pathways were active in astrocytes (Lovatt et al. 2007). 
 
Analogy with previous heart studies 
The idea to use the washout rate k2 of 1-11C-acetate as a marker of CMRO2 was inspired by earlier 
studies performed in the heart (Armbrecht et al. 1990; Buck et al. 1991; Lindner et al. 2006). In 
those studies it was clearly established that k2 reflects myocardial oxygen consumption in a linear 
fashion. One rough indication that this approach may be also valid in the brain is derived from the 
following estimation. In the dog heart the relationship between CMRO2 and k2 was CMRO2 
[ml/min/100g] = 48.8 ml/100g x k2 [min-1]. Application of this relationship to this study yields an 
astrocytic CMRO2 of 0.7 ml/min/100g in rats and humans at baseline. This amounts to 
approximately 20 % of whole brain oxygen consumption (3.4 ± 0.28 ml/min/100g in man (Kety and 
Schmidt 1948)).This value compares favorably to published values for the fraction of astrocytic 
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ATP generation by oxidative processes (Hertz and Kala 2007; Hertz et al. 2007; Oz et al. 2004) 
which are in the range of 14 to 30 %.   
 
Is k2 specific for astrocytic metabolism? 
One important observation in this regard is that labeled acetate is only taken up by astrocytes and 
not neurons (Waniewski and Martin 1998). However, a fraction of the label will eventually end up in 
neurons as labeled glutamine/glutamate (via the glutamate/glutamine cycle), which was produced 
via the α-ketoglutarate-glutamate step in the astrocytes. Nevertheless, the transfer of labeled 
glutamine to neurons is slow relative to the 20 minute acquisition time of this study. Lebon et al 
investigated astrocytic energy metabolism using nuclear magnetic resonance spectroscopy and 2-
13C-acetate in humans (Lebon et al. 2002). They concluded that the labeled glutamine/glutamate 
observed during the first 20 minutes following the start of the 2-13C-acetate infusion reflected 
astrocytic glutamate only. It therefore seems reasonable to assume that most of the 11C activity 
measured in our study was originating from astrocytes. Even if a small fraction of labeled 
glutamine/glutamate had reached the neurons, the contribution of neuronal 11C-CO2 production 
could be expected to have been small. Hertz et al. (Hertz et al. 1988) demonstrated in cell cultures, 
that glutamate oxidation of neurons was at most 25 percent of the one in astrocytes. In addition, 
recent work found a 4.3-fold higher expression of the enzyme glutamate dehydrogenase Glud1 in 
astrocytes, also suggesting a substantially higher capacity for astrocytes to metabolize glutamate 
(Lovatt et al. 2007). 
 
Comparison of the k2 method with autoradiography 
Cruz et al investigated the accumulation of 2-14C-acetate during acoustic stimulation in rats (Cruz 
et al. 2005) using autoradiography performed 5 minutes following tracer injection. They reported a 
15-18% increase of 2-14C-acetate uptake in the stimulated compared to the contralateral 
structures. These results are in line with our experiments. At 5 minutes the uptake of 1-11C-acetate 
was 14 % higher in the stimulation compared to the baseline experiments (Figure S1; 
supplementary data). This value was calculated by simulating tissue time activity curves with a 
mean input curve and the mean K1 and k2 values of the stimulation and baseline experiments. 
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Here, it is crucial to point to an important difference in the methodology. By evaluating just one 
time-point as in autoradiographic studies, it is not easy to determine to what degree the differential 
uptake is influenced by increased blood flow, although this influence seems to be low for acetate 
(Dienel et al. 2007), but probably not negligible as our demonstration of a small K1 increase during 
stimulation suggests. To separate delivery and washout a kinetic approach as chosen in this study 
seems advantageous. On the other hand autoradiographic studies deliver images and, when using 
the long-lived 14C, allow an easier determination of metabolites. 
Using the short-lived isotope 11C we simply concentrated on two aspects of the label kinetics, 
delivery and washout. We cannot deliver any data concerning the fate of the label between these 
steps which may be very complex. An indication of this complexity is demonstrated in the model of 
Figure 6. Previous work by Berl et al. (Berl and Frigyesi 1969) demonstrated a) that 5 minutes 
following injection of 1-14C-acetate most label is found in amino acids and b) that there is a decline 
of their concentration afterwards. This may indicate that most acetate oxidation happens indirect 
via amino acids. More extended information on the fate of the label is found elsewhere (Berl and 
Frigyesi 1969; Dienel et al. 2007). Nevertheless, still more studies are needed to identify the 
contribution of acetate and TCA cycle metabolites as direct substrates for oxidative metabolism. 
 
General remarks 
Due to the delay of the onset of the label washout k2 is smaller during the first minutes following 
injection. This effect was not taken into account in the tracer kinetic modeling, e.g. k2 was assumed 
constant. To estimate the resulting error we calculated simulated tissue time-activity curves with k2 
= 0 during the first 5 minutes and = 0.027 min-1 thereafter. The refit of these curves using a 
constant k2 demonstrated only a 1.5 % change of k2.  
Another point concerns parameter identifiability. The sensitivity analysis demonstrated that the 
dependence of tissue activity on k2 is more pronounced at the higher values, implying that the k2 
values during baseline are less reliable than during stimulation. This aspect and the fact that k2 at 
baseline is relatively small may lead to a relatively large error margin in the ratio k2simulation/k2baseline. 
We also did not consider the effect of blood-borne 11C-CO2 on K1 and k2. Most of the CO2 in blood 
is converted to HCO3¯ which does not cross the blood brain barrier. Approximately 5 percent of 
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total HCO3¯/CO2 is present as dissolved 11C-CO2 (Brooks et al. 1984) which freely penetrates the 
brain. We constructed simulated tissue time activity curves using the one-tissue compartment 
model and the blood-borne 11C-CO2 as a second input curve. K1 and k2 values for this fraction of 
CO2 were taken from Brooks et al. (Brooks et al. 1984). These tissue time activity curves were then 
refitted using the standard one-tissue compartment model not considering blood borne 11C-CO2. 
The deviation of the K1 and k2 values was less than 1.5 percent, demonstrating that the effect of 
blood-borne 11C-CO2 on K1 and k2 is negligible. 
 
 
Summary 
 
1-11C-acetate seems a promising tracer to investigate astrocytic oxidative metabolism in animals 
and humans. If the washout rate is indeed representing the production of 11C-CO2, then its 
increase during stimulation would point to a substantially higher astrocytic oxidative metabolism 
during brain activation. However, the quantitative relationship between k2 and CMRO2 needs to be 
determined in future experiments. 
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Appendix 
 
Details of beta probe experiments and human PET measurements 
 
Blood and tissue processing 
a) Physiological blood parameters 
Several blood gas variables (pH, pCO2, pO2) relevant to cerebral energy metabolism were 
measured with a pH/blood gas analyzer (AVL, Compact 3, Roche Diagnostics, Switzerland) before 
the start of tracer kinetic measurements. Plasma lactate levels were determined before the first 
tracer injection in 24 animals (Ektachem DT, Kodak, USA). In animals of group V (dichloroacetate 
challenge) lactate levels were determined twice, before and 4 hours after injection of 
dichloroacetate respectively. (Ektachem DT, Kodak, USA). In 5 animals there were technical 
problems with the analyzer rendering a measurement impossible. 
 
b) Determination of the arterial plasma input curve 
For the CBF measurements arterial blood was continuously drawn during scanning and the activity 
in the catheter was measured in a coincidence counter (GE Medical Systems) which was cross 
calibrated with the beta scintillator and the PET scanner respectively. During the 1-11C-acetate 
scan arterial radioactivity was also measured online for the total scan time in the animal 
experiments (for an example of acquired time activity curves see Figure 1). In the human study it 
was acquired online only for the first five minutes so as not to miss the peak of the arterial input 
curve, thereafter for the remaining 15 minutes four single samples were taken manually at different 
time points (around 3, 6, 15 and 25 minutes) and processed as described below. Whole blood 
activity was then corrected for a) a different tracer concentration in whole blood and plasma and b) 
the build-up of labeled metabolites. The ratio “11Cplasma/11Cwhole blood“ was determined in all animals at 
different time-points (3 blood samples per injection). The data of all animals were then pooled and 
the time course of the ratio was approximated by fitting a quadratic polynomial to the data. This 
function was then used to convert counts in whole blood to counts in plasma. In humans, the 11C 
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concentration in whole blood (CB) was first converted to 11C concentration in plasma (CPL) using 
the same conversion function as determined in rats.  
Secondly, plasma activity was corrected for the build-up of labeled metabolites using data from 
previous 1-11C-acetate studies in the human heart (Buck et al. 1991). 
 
c) Metabolite analysis in blood 
Three blood samples (about 400 μl each) were collected at different time points during each 20 
minutes acquisition for analysis of authentic tracer and metabolites. These samples were first 
centrifuged for 3 minutes at 2000 rpm. Proteins were then precipitated with 75 μl acetonitrile in 50 
μl plasma. After a second centrifugation for 3 minutes at 2000 rpm, the composition of the 11C-
derived radioactivity in the supernatant (80 μl) was analyzed by high-pressure liquid 
chromatography (HPLC) on a polymeric column (PRP-1, 5-μm, 250 × 4.1 mm i.d., Hamilton, 
U.S.A.) with 3 mmol/l phosphoric acid in water (pH 2.67) as the mobile phase (1 ml/min). The 
amount of authentic tracer was expressed as a fraction of total plasma 11C counts (f).  
The fraction data of all animals was then pooled and the time-course of the fraction was 
approximated by a decaying exponential function of the form function f = 1-α(1-exp(-μt)). This 
function was subsequently employed to convert the total plasma activity to the time-course of 
authentic 1-11C-acetate (= input curve). 
 
 
Data analysis 
In the animal and human studies the analytical and statistical methods were similar as described 
below. All calculations were performed using the software package PMOD ((Mikolajczyk et al. 
1998); PMOD Technologies, Adliswil, Switzerland). 
 
a) CBF measurements 
The basis of the calculation for CBF measurements was the one-tissue compartment model 
including a partition coefficient for H2O (see Figure 6A). The change of the radioactivity 
concentration in tissue CT is then defined by the following differential equation
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dCT/dt=CBF(CA(t)-CT(t)/p) (1) 
 
where CA is the arterial tracer concentration and p is the tissue partition coefficient, e.g that fraction 
of tissue that is permeable for H215O. In this configuration CT is the concentration of H215O in 1 ml 
of brain and it is assumed that H215O immediately reaches a homogeneous concentration in 
permeable space and no division into a vascular and a tissue compartment is necessary. The 
analytical solution of (1) is  
 
CT=CBF exp (-CBF/p t)  CA (2) 
 
where  means mathematical convolution.  
 
Equation 2 was fitted to the data using least squares fitting (Marquardt algorithm) implemented in 
the software PMOD (Mikolajczyk et al. 1998). Prior to data analysis tissue TACs and arterial input 
curves were corrected for physical decay of 15O. 
 
With the human H215O PET data we calculated quantitative parametric maps representing regional 
cerebral blood flow (rCBF) using the integration method described by Alpert (Alpert et al. 1984). 
This method yielded maps of K1 and k2 which represent rCBF and rCBF/p respectively (p = 
partition coefficient). Before calculation of the parametric maps, the input curve was corrected for 
delay and dispersion.  
 
 
b) 1-11C-acetate experiments 
The investigated method consisted of standard compartmental modeling using an arterial input 
function. Tracer kinetic modeling was performed using the one-tissue compartment model depicted 
in Figure 6B.  
 
⊗
⊗
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K1 :  describes uptake of tracer across the blood brain barrier. K1 is related to the first pass 
extraction fraction (EF) and CBF through the following equation: K1= EF x CBF. This equation was 
used to determine EF in the animal and human experiments. 
  
k2 :  represents back-diffusion of radioactivity from tissue to vascular space 
 
Tracer exchange between the compartments is described by the following differential equation 
 
    
 (3)  
 
    
 
Since the total activity measured in a region is composed of counts from tissue and blood, all 
models contained a parameter (α) correcting for blood activity. 
    
 (4) 
      
where 
CVOI: in the human PET study, CVOI is the 11C activity concentration in the defined volume of 
interest, in the animal study it is the 11C activity measured by the tip of the beta scintillator. 
α:  percentage of intravascular space in tissue  
CT:  Activity in the extra vascular compartment  
CB:  total blood activity 
 
CT was calculated by numerical integration of the differential equations. The correction for the 
contribution of blood in the brain (α) was fixed at 0.05. This value considers that signals originating 
from large superficial pial vessels impact the beta scintillator measurements.  
p
T CT k C K dt 
dC 
2 1 −= 
BT i voi C C C α α + −= )1(
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Delay of onset of radiolabel washout 
To check whether the start of the radioactivity washout from tissue was delayed, the first 5 minutes 
of data following tracer injection were refitted with only k2 as a free parameter and K1 fixed to the 
full length fit.  
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Figures of Chapter l: 
Stimulation-induced Increases of Astrocytic 
Oxidative Metabolism in Rats and Humans 
investigated with 1-11C-Acetate 
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Figure l-1. Acquired time activity curves of 1-11C-acetate and plasma fraction of true 
1-11C-acetate 
 
In the upper panel the time course of 11C radioactivity in whole blood (●), plasma (□) and brain 
tissue (▼) acquired over 20 minutes is shown. In addition the model fit is demonstrated (straight 
line, K1 = 0.085 ml/min/ml tissue, k2 = 0.015 min-1). The goodness-of-fit is demonstrated by the 
random distribution of the residuals, demonstrated in the insert. 
In the lower panel the fraction f of true 1-11C-acetate in plasma in animal and human studies is 
plotted. The filled circles represent data points from animal studies (anesthetized rats) and the 
solid line is the corresponding fit of the function f = 100-α(1-exp(-µt)). Least squares fitting yielded  
α = 93 % and  µ = 0.11 min-1. In the human study (open circles; conscious humans), α and µ were 
taken from previous experiments which had yielded very similar values (α = 91%, µ = 0.13 min-1) 
(Buck et al. 1991). 
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Figure I-1 
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Figure l-2. Label washout is increased during stimulation after a delay 
 
The top and middle graph demonstrate time activity curves of 11C activity in rat brain tissue 
normalized to injected activity per g bodyweight yielding standardized uptake values (SUV). The 
curves represent mean data from 5 experiments. In the baseline-baseline experiments (top panel) 
the curves appear identical. In contrast, the washout of 11C activity is remarkably larger during 
stimulation (middle panel). The bottom panel illustrates the residuals between fit and data if only 
the first 5 minutes of data are fitted. Such a short fit yields substantially lower initial washout rates 
than a 20 minute fit, demonstrating that the onset of the washout of radiolabel from tissue is 
delayed. 
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Figure I-2 
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Figure l-3. Summary of animal data 
 
Panels A and B demonstrate the reproducibility of parameters K1 and k2. There was no significant 
change of K1 and k2 between sequential baseline experiments. Panels C and D show the increase 
of K1 and k2 during infraorbital nerve stimulation. The values of k2 following the administration of 
dichloroacetate (DAC, 50 mg/kg) at baseline and during infraorbital nerve stimulation are 
demonstrated in panel E. The p values were calculated using the Wilcoxon Signed Rank test. 
Values are given as mean ± SD. 
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Figure l-3. 
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Figure l-4. Clearance of 11C activity is also increased during stimulation in human 
visual cortex 
 
Time-activity curves of 1-11C-acetate uptake in the human visual cortex normalized to injected 
activity per kg bodyweight yielding standardized uptake values (SUV). The curves represent mean 
data from all 6 human experiments. During visual stimulation the clearance of 11C activity is larger 
compared to baseline. Note also the modestly faster wash-in of radioactivity during stimulation. 
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Figure l-4 
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Figure l-5. Summary of human data 
 
Summary of human data. The change of CBF from baseline to visual stimulation in the 3 examined 
brain areas is demonstrated in the top panels, the one of K1 and k2 of 1-11C-acetate in the middle 
and bottom panels respectively. The p values were calculated using Wilcoxon Signed Rank test. 
Values are given as mean ± SD. 
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Figure l-5 
 
 
 
 
Chapter I – 1-11C-acetate 
 
 
84 
 
Figure l-6. Compartment models used for data analysis 
 
One-tissue compartment models used in animal and human studies to analyze CBF using H215O 
(A) and the kinetics of 1-11C-acetate respectively (B). K1 describes the transfer of acetate from 
blood to tissue whereas k2 corresponds to the flux of radiolabel from tissue to blood. Labeled 
acetate in tissue (Cac-tiss) is converted to acetyl-CoA, catalyzed by acetyl-CoA synthetase. Acetyl-
CoA then enters the TCA cycle, where the label can either be transferred to CO2 or metabolites 
(Cm-tiss) such as glutamine and glutamate which were produced via α-keto-glutarate. Some 
labeled metabolites will reenter the TCA cycle at the α-keto-glutarate level and in this way yield 
more labeled CO2. In theory, k2 denotes the backdiffusion of all labeled species from tissue. 
However, as discussed in the main text, we argue that the loss of label is mainly due to 
backdiffusion of 11C-CO2, and that the rate of this label loss, described by k2, is reflecting the 
production of CO2 and is therefore closely related to oxidative metabolism.  
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Figure l-6 
 
 
 
 
  
Chapter I – 1-11C-acetate 
 
 
86 
 
Supplementary Information 
 
Supplementary Figure S1.  
 
Tissue time activity curves are shown using a mean input curve and the mean K1 and k2 values of 
the stimulation and baseline experiments in anesthetized rats respectively. Note the higher uptake 
of 1-11C-acetate (+ 14 %) after 5 minutes in the stimulation experiments. 
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Abstract 
 
Introduction: There is considerable debate in the neuroscience community regarding cerebral 
lactate metabolism. The purpose of this study was to examine the kinetics of 1-11C-L-lactate in the 
rat brain with the goal to use it for the investigation of neuronal lactate oxidation and neuronal 
oxidative metabolism in general. Methods: The study was performed in anesthetized adult 
Sprague Dawley rats. Following the injection of 200 – 300 MBq of 1-11C-L-lactate, 20 minutes of 
data were recorded using a beta scintillator. The arterial input curve was determined by 
continuously monitoring the 11C activity in a femoral a-v shunt and subsequent metabolite 
correction. Acquisitions were performed either during baseline or during electrical infraorbital nerve 
stimulation. In a second part of the study it was possible to use a novel high-sensitivity beta probe 
enabling two tracer injections in the same animal allowing intra-animal comparisons. Finally, 
lactate transport was pharmacologically blocked in two animals and the effect on the kinetics was 
investigated. Data were analyzed using a one-tissue compartment model containing the rate 
constants K1 and k2.  
Results: In the inter-animal comparison no difference of the kinetics during the two different 
activity states could be observed. K1 and k2 during baseline were 0.105 ± 0.03 (mean ± sd) ml * 
min-1 * mltissue-1, and 0.089 ± 0.03 min-1, during stimulation 0.111 ± 0.04 ml * min-1 * mltissue-1, and 
0.086 ± 0.02 min-1, respectively. In contrast, the intra-animal comparison showed an increased k2 
(on average +24% from baseline) during stimulation. Blockade of lactate transport largely reduced 
both lactate influx (K1) and k2. 
Conclusion: 1-11C-L-lactate is a feasible tracer for brain studies in vivo. Provided that lactate 
uptake is limited to neurons, the increase of the label washout rate during stimulation indicates that 
the tracer may be closely related to neuronal oxidative metabolism.   
 
Key words: beta scintillator, kinetic modeling, neuronal lactate oxidation, radiolabeled L-lactate  
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Introduction 
 
The presence of lactate in the brain has been considered for a long time as a threat to proper brain 
function and as a sign of tissue suffering. Therefore, the finding that lactate is efficiently oxidized to 
CO2 in different neuronal preparations, sometimes even preferred to glucose (Bouzier-Sore et al. 
2003a; Larrabee 1995; Larrabee 1996; McKenna et al. 2001; Schurr et al. 1999; Tabernero et al. 
1996), is surprising. Evidence that neurons oxidize lactate as a metabolic substrate to satisfy at 
least in part their energy needs was provided with different approaches also in vivo. Magnetic 
resonance spectroscopy studies showed that intravenously injected lactate was readily 
metabolized by the brain in a compartment lacking pyruvate carboxylase activity (Bouzier et al. 
2000; Hassel and Brathe 2000). Because pyruvate carboxylase activity is found only in astrocytes 
(Hertz 2004), it was suggested that lactate oxidation occurs predominantly in neurons. Additionally, 
it was concluded from the labeling pattern of compounds such as glutamine, glutamate and γ-
aminobutyric acid (GABA), that lactate must be used in large parts by glutamatergic neurons (Qu 
et al. 2000). An indirect in vivo confirmation of the preferred use of lactate over glucose by the 
brain was obtained in human subjects using positron emission tomography (PET) and 18F-
fluorodeoxyglucose. Smith and coworkers (2003) found that raising plasma lactate levels to values 
reached during moderate exercise substantially reduced brain glucose utilization, suggesting 
preferential lactate use by the brain. Despite of all this in vivo evidence, the insight in cerebral 
lactate oxidation is still weak and new approaches for the investigation of lactate use in situ are of 
interest.  
Tracer kinetic measurements using radiotracer methods such as beta scintillators and PET provide 
powerful approaches for the in vivo determination of biochemical and physiological processes. If 
lactate is preferentially taken up and oxidized by neurons, then tracer studies with radiolabeled 
lactate may be a feasible method to gain more insight into neuronal energy metabolism. 
Furthermore, we hypothesize that the lactate tracer kinetics will not only probe the neuronal lactate 
metabolism but also total neuronal oxidative metabolism. Based on this hypothesis we evaluated 
the kinetics of 1-11C-L-lactate in the rat brain at baseline and during various manipulations using a 
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beta scintillator. Topics of interest were the question if the tracer exhibits feasible kinetic 
characteristics enabling in vivo cerebral tracer studies and the evaluation of possible changes at 
increased activity of the brain.  
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Material and methods 
 
Tracer production 
1-[11C]lactic acid enantiomers were produced as described elsewhere (Drandarov et al. 2006). In 
short, racemic 1-[11C]lactic acid was made by [11C]cyanohydrine synthesis starting from [11C]HCN 
(trapped as [11C]KCN) and acetaldehyde bisulfite adduct. The quantitatively formed 1-[11C]-DL-
lactonitrile was hydrolyzed by reflux in concentrated HCl and the reaction mixture was introduced 
directly into a semipreparative polymeric HPLC column (Phenomenex, Polymerx 10μ, 250x10 mm, 
0.03% H3PO4 as the mobile phase) where the product was isolated from the aggressive reaction 
matrix. Then the collected racemic 1-[11C]lactic acid was automatically introduced into a 
preparative chiral HPLC column coated with a penicillamine derived chiral selector and eluted with 
1 mM CuSO4 solution as the mobile phase where both enantiomers were separated by ligand 
exchange chromatography. The fractions corresponding to [11C]-D- or [11C]-L-lactic acid, were 
passed through anion exchanger Sep-Pak® cartridges (Accell™ Plus QMA, in CO32- form) where 
the Cu2+ ions (as insoluble carbonate) and the [11C]-lactate are retained. The latter was selectively 
washed out from the cartridges with 2 mmol/L sodium phosphate buffer pH 7.4 to obtain injectable 
solutions of pure Na-[11C]-D- and L-lactate enantiomers. The quality control of the final product was 
done by chiral ligand exchange HPLC. The procedure lead to a product of >99 %  chemical and 
enantiomeric purity. The specific activity at the end of synthesis was about 400 GBq/μmol.  
 
Animals 
The study included 22 male Sprague-Dawley rats weighing 245 to 327 g. Four animals were 
excluded from final analysis due to problems during surgery or during the experimental 
acquisitions. Finally 18 animals were included in the analysis. The experiments were carried out by 
licensed investigators and approved by the local veterinary authorities. The animals were kept in 
cages with standardized conditions of light (day/night-cycle 12h/12h) and temperature and free 
access to food and water. Before the experiments the animals were fasted overnight. 
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General animal preparation 
Surgery was performed under isoflurane anesthesia (3.5% in air/oxygen 70%/30%) and involved 
the placement of an arteriovenous shunt (a-v shunt) from the right femoral artery to the right 
femoral vein and tracheotomy for mechanical ventilation. The actual experiment was performed 
under urethane anesthesia (1400 mg/kg i.p.). The a-v shunt was used for the injection of the 
tracer, for the collection of blood samples, for the continuous monitoring of arterial blood pressure 
and for the online acquisition of total arterial 11C activity. For the latter purpose, the shunt was run 
through a coincidence scintillator (GE Medical Systems) that stored at 1-second intervals. The 
online arterial sampling procedure is described in detail elsewhere (Weber et al. 2002a).            
 
Beta scintillator studies  
Two different systems were used in this study. For a first series of experiments a single channel 
system with a intracortical probe was used. The beta scintillator (Swisstrace GmbH, Zurich, 
Switzerland) has been described in detail earlier (Weber et al. 2003; Wyss et al. 2007). In brief, it 
consists of a scintillation tip (Bicron, BF412, Newbury, OH, USA) with a length of 1 mm and a 
diameter of 0.25 mm attached to a high numerical aperture glass fiber. As described below in a 
second group of animals a recently developed two channel system with surface probes could be 
utilized. These devices consist of larger scintillator crystals with a thickness of 0.2 mm and a 
diameter of 3 mm leading to a higher sensitivity.  
The scintillators were made light-tight by applying a uniform coating of silver particles. The 
scintillations were measured using a photomultiplier tube and counting electronics (Perkin Elmer, 
Massachusetts, USA). The limited range of beta particles within biological tissues leads to a limited 
detection volume centered around the scintillating tip of the probe. Monte Carlo simulations 
demonstrated that for C-11 the distance required to detect 90 % of the beta particles around the 
probe is 2.0 mm (Pain et al. 2002b). The sensitivities of the used beta scintillators were 0.036 to 
0.047 cps/kBq/cc and 0.31 to 0.60 cps/kBq/cc for the intracortical and the surface probe device, 
respectively. 
The intracortical scintillator was inserted into the primary somatosensory cortex using a 
stereotactic frame (David Kopf Instruments, Tujunga, CA, USA). The skull was exposed and a
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craniotomy was performed using a dental drill. The dura was carefully incised at the insertion 
position, which was (according to Bregma) 2 mm posterior and 5 mm lateral. This position was 
adjusted to avoid large superficial blood vessels. The scintillator was carefully lowered to a depth 
of 1.4 mm. In experiments with the surface probe system the detector was adjusted just above the 
thinned skull at the same coordinates. The count rate was stored on a personal computer using a 
bin width of 1 second yielding tissue time activity curves (TACs). Following each experiment the 
beta scintillator was calibrated with known concentration of 11C activity. For data analysis all data 
were background-corrected (range of background count rates: 0-2 cps for the intracortical system 
and 2-8 cps for the surface probe system), decay corrected to the time point of injection and 
converted to kBq/ml. 
In the stimulation experiments, the efficiency of the stimulation and the correct positioning of the 
beta probe was verified by Laser Doppler flowmetry (Periflux System 5000, Perimed AB, Järfälla, 
Sweden).  
 
Experimental protocols 
a) Intracortical probe 
In a first group of 6 animals the time-course of 1-11C-L-lactate was measured at baseline. Twenty 
minutes of data were acquired after injection of 200-300 MBq (diluted in 0.5 mL) of tracer. In 4 of 
these animals baseline cerebral blood flow (CBF) was determined prior to 1-11C-L-lactate injections 
using H215O and the methodology described previously (Weber et al. 2003). The first pass 
extraction fraction (EF) was calculated using the relationship EF = K1/CBF where K1 is the 
transport parameter describing tracer transport from blood to tissue.  
.  
In a second group of 7 animals TACs were acquired during electrical infraorbital nerve stimulation 
to elicit increased brain activity. The current was adjusted to 2 mA and 2 Hz stimulation frequency 
was chosen because previous experiments using 18F-fluorodeoxyglucose autoradiographies 
demonstrated this frequency to be optimal eliciting a maximal increase in glucose consumption of 
about 70 to 80 % (unpublished data). The stimulation started 30 seconds prior to tracer injections.  
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b) Surface probe 
In total, in 5 animals 1-11C-L-lactate experiments were performed with a novel surface probe, 
developed and evaluated in our lab. In this set of experiments two subsequent tracer injections 
were possible in the same animal due to the improved sensitivity of the system. In 3 animals one 
acquisition was performed during baseline conditions and the other during electrostimulation. The 
order was changed between single experiments to check for a potential order effect. Finally, in 2 
animals the effect of blockade of the monocarboxylic acid transporters using α-cyano-4-hydroxy-
cinnamate (4-CIN) on the kinetics of 11C-L-lactate was tested. The MCT blocker was injected 
intraperitoneally in a concentration of 90 mg/kg 30 min prior to the tracer injection. The 
permeability of the blood brain barrier to 4-CIN has been shown previously (Schurr et al. 2001). 
 
Data acquisition and analysis 
a) CBF measurements 
The basis of the calculation of the CBF measurements was the one-tissue compartment model 
including a partition coefficient for H215O (see Figure 1A). The change of the radioactivity 
concentration in tissue Ctiss is then defined by the following differential equation 
 
dCtiss/dt = CBF(Ca(t)-Ctiss(t)/p) (1) 
 
where Ca is the arterial tracer concentration and p is the tissue partition coefficient, e.g. that 
fraction of tissue that is permeable for H215O. In this configuration Ctiss is the concentration of H215O 
in 1 ml of brain and it is assumed that H215O immediately reaches a homogeneous concentration in 
permeable space and no division into a vascular and a tissue compartment is necessary. The 
analytical solution of (1) is  
 
Ctiss = CBF * exp (-CBF/p t) ⊗  Ca (2) 
 
where ⊗  signifies mathematical convolution.  
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Equation 2 was fitted to the data using least squares fitting (Marquardt algorithm) implemented in 
the software PMOD ((Mikolajczyk et al. 1998); PMOD Technologies, Adliswil, Switzerland). Prior to 
data analysis tissue time activity curves and arterial input curves were corrected for physical decay 
of 15O. 
 
b) 1-11C-L-lactate experiments 
The investigated methods consisted of standard compartmental modeling using an arterial input 
function. Tracer kinetic modeling was performed using the one-tissue compartment model depicted 
in Figure 1B.  
 
K1:  describes uptake of tracer across the blood brain barrier and is related to blood flow 
(CBF) and the first pass extraction fraction EF (K1= CBF * EF).  
 
k2:  represents backdiffusion of label from tissue to vascular space.  
 
Tracer exchange between the compartments is described by the following differential equations 
 
dCtiss/dt = K1Cplasma(t) – k2Ctiss(t) (3)   
  
Since the total activity measured in a region is composed of counts from tissue and blood, all 
models contained a parameter (α) correcting for blood activity. 
 
CVOI = (1 – α)Ctiss + αCblood (4) 
        
where 
CVOI:  11C activity measured by the tip of the beta scintillator 
α:  percentage of intravascular space in tissue  
Ctiss: Activity in the extravascular compartment 
Cblood:  total blood activity 
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Ctiss was calculated by numerical integration of the differential equations. The vascular fraction α 
was included as a fit parameter which improved the least square fit as compared to a fixed value of 
α = 5%. 
 
Model adjustments for the dual-injection paradigm 
The kinetic model was adjusted in two ways for the analysis of the dual-injection data of the study 
part using the surface probe: (1) Two sets of rate constants (K1, k2) were used in the calculation of 
the operational equation. The first set for the time until the second injection, and the second set 
thereafter. The least-squares fit procedure resulted in estimates for all 4 rate constants and the 
vascular fraction. (2) The correction function to derive plasma activity from whole blood activity was 
adjusted to distinguish between the contributions from to the two injections. To this end, blood 
activity from the first injection was extrapolated using an exponential function which was fitted to 
the blood activity 10 minutes before the second injection.    
 
Blood and tissue processing 
a) Physiological blood parameters 
Several blood gas variables (pH, pCO2, pO2; AVL, Compact 3, Roche Diagnostics, Switzerland) 
and metabolic measures such as plasma glucose and lactate levels (Ektachem DT, Kodak, USA) 
which are relevant parameters influencing lactate uptake in the brain were measured in all animals 
before the start of tracer kinetic measurements. Ventilation was adjusted according the blood gas 
values to reach physiological blood gas values.  
 
b) Determination of the arterial plasma input curve 
The total radioactivity in arterial blood was continuously recorded over 40 minutes using the 
coincindence counter (GE Medical systems). Whole blood activity was then corrected for a) a 
different tracer concentration in whole blood and plasma and b) the build-up of labeled metabolites. 
The ratio „11Cplasma/11Cwhole blood“ was determined in all animals at different time-points (3 to 4 blood 
samples per animal). The data of all animals were then pooled and the time-course of the ratio was
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approximated by fitting a quadratic polynomial to the data. This function was then used to convert 
counts in whole blood to counts in plasma.  
 
c) Metabolite analysis in blood 
Samples (about 400 μL) were collected at different time points after tracer injection, with a 
maximum of 4 blood samples per animal, to determine the time-course of the ratio of the 11C 
activity in plasma to whole blood and for analysis of authentic tracer and metabolites. These 
samples were first centrifuged for 3 minutes at 2000 rpm. Proteins were then precipitated with 75 
μL acetonitrile in 50 μL plasma. After centrifugation for 3 minutes at 2000 rpm, the composition of 
the 11C-derived radioactivity in the supernatant (80 μL) was analyzed by high-performance liquid 
chromatography (HPLC) on a polymeric column (PRP-1, 5-μm, 250 × 4.1 mm i.d., Hamilton, 
U.S.A.) with 3 mmol/L phosphoric acid in water (pH 2.67) as the mobile phase (1 mL/min).The 
retention times of 11C-HCO3−  (3.3 min) and lactic acid (5.1 min) were determined by using aqueous 
solution of NaHCO3 and DL-lactic acid as reference compounds, detected by UV absorption at 220 
nm. The amount of authentic tracer was expressed as a fraction of total plasma 11C counts (Figure 
2).  
The fraction data of all animals was then pooled and the time-course of the fraction was 
approximated by a decaying biexponential function. This function was subsequently employed to 
convert the total plasma activity to the time-course of authentic 11C-lactate (= input curve). 
 
d) Metabolite analysis in brain 
At the end of the experiment the rats were perfused with PBS and brains were prepared for 
measurements with the HPLC system. 
Each brain was first homogenized before adding acetonitrile (150%). The subsequent procedure 
was the same as with the blood samples described above, except that the amount of supernatant 
injected into the HPLC system was 200 µL. 
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Results 
 
The pH and the arterial blood gases were all within physiological ranges (pH = 7.35 – 7.45; pCO2 
= 35 – 45 mmHg; pO2 = 70 – 100 mmHg). Arterial plasma glucose (9.2 ± 2.5) and lactate (2.0 ± 
0.6) levels were in physiological ranges in all animals and no differences between the groups were 
evident. In the two experiments with blockade of MCT transporters using 4-CIN an increase of the 
blood lactate levels was evident from 2.0 to 2.9 (mean of two animals).  
 
Baseline kinetic properties 
First pass extraction fraction and baseline kinetics in brain 
CBF was measured in 4 baseline experiments and was 41 ± 15 ml/min/100g. The first pass 
extraction fraction calculated from EF = K1 / CBF was 29.99 ± 10.4 % in these experiments.  
  
Metabolite accumulation in arterial blood 
11C-CO2 turned out to be the only identified metabolite in blood measured by HPLC. The time 
course of the fraction of authentic tracer in arterial plasma is demonstrated in Figure 2. Metabolite 
build-up is fast for 1-11C-L-lactate. At 20 minutes the fraction of true tracer in plasma dropped to 
about 40 % and furthermore to about 20 % at 40 minutes. The ratio of total 11C activity in plasma 
and whole blood (plasma/whole blood) was stable. It was 1.38 ± 0.07 at 4 minutes and 1.40 ± 0.1 
at 40 minutes. 
Metabolite analysis of perfused brain tissue at the end of the experiment revealed 58 ± 8 % lactate 
and 42 ± 8 % CO2. No difference was manifest between baseline and stimulation condition.                                
 
Tissue kinetics during baseline 
Delivery to the brain (K1) was 0.106 ± 0.025 ml*min-1*ml tissue (mean ± sd). The time activity 
curves of 1-11C-L-lactate at rest demonstrate a considerable washout after a peak at 4 minutes. 
The rate constant describing washout was k2 = 0.089 ± 0.03 min-1. At 20 minutes the tissue activity 
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dropped to 65 percent of the peak value. The one-tissue compartment model was adequate to fit 
the 1-11C-L-lactate data as indicated by the random distribution of the residuals in Figure 3.  
 
Lactate kinetics during electrical infraorbital nerve stimulation 
The efficacy of the stimulation was confirmed by an increase of the LDF signal by 20-25% (data 
not shown). 
 
Intracortical probe – inter-animal comparison      
The inter-animal comparison did not yield any significant difference in the k values of baseline and 
stimulation. A likely reason is the large inter-animal variation as demonstrated in Figure 4. 
 
Surface probe – intra-animal comparison 
Our two channel probe system made the simultaneous measurement of radiotracer kinetic time 
courses at two different locations possible. Furthermore, the higher sensitivity of this system 
enabled us to perform two subsequent injections from one tracer production in the same animal. In 
the intra-animal comparison (n = 3) we observed a clear increase of the washout constant k2 from 
baseline to stimulation (mean increase of k2: +24 %; Figure 5A). In contrast, the difference 
between the two hemispheres at rest was only 3 % (Figure 5B). On the ipsilateral side (Figure 
5C) the mean increase of k2 from baseline to stimulation was 6 %. 
 
MCT blockade using α-cyano-4-hydroxy-cinnamate (4-CIN) 
Blockade of the cerebral MCT transporters using 4-CIN led to a large reduction of lactate uptake 
(K1, -62%) and label washout (k2, -53%) as shown in Figure 6. 
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Discussion 
 
In this study we present for the first time the use of 1-11C-L-lactate for in vivo experiments in the 
brain. This work was motivated by the perspective of developing a tracer to examine neuronal 
metabolism in the living brain. Lactate use by neurons as an energy substrate in vivo has been a 
highly debated issue for decades. It is well established that neurons can oxidize lactate. As 
elaborated in the introduction, neuronal lactate oxidation has been demonstrated in several 
neuronal preparations. In addition, it has been shown that synaptic activity can be maintained in 
slices by lactate in the absence of glucose (McIlwain 1953; Schurr et al. 1988). The situation is 
less clear in the intact brain. The debate focuses particularly on the amount of lactate oxidized by 
neurons in vivo (Bonvento et al. 2005; Chih and Roberts Jr 2003; Korf 2006; Pellerin and 
Magistretti 2003). The astrocyte neuron lactate shuttle hypothesis (Magistretti 1999; Pellerin and 
Magistretti 1994) states, that a major fraction of the neuronal energy expenditure is covered by the 
oxidation of lactate which is produced in the astrocytes and shuttled to the neurons (for an update 
see (Pellerin et al. 2007)). In the past, magnetic resonance spectroscopy (MRS) has been the 
exclusive method for the investigation of 13C-labeled lactate in the intact brain (Bouzier et al. 2000; 
Hassel and Brathe 2000; Qu et al. 2000; Serres et al. 2004; Serres et al. 2005; Serres et al. 2003). 
By analyzing the evolution of label in brain extracts after the injection of 13C labeled lactate these 
authors could show that cerebral lactate metabolism contributed up to 50 % of that of glucose 
(Bouzier et al. 2000; Hassel and Brathe 2000). More specifically, it was suggested that more 
pyruvate coming from lactate than from glucose was metabolized in neurons (Qu et al. 2000). 
Furthermore, the contribution of lactate to cerebral metabolism seems to be activity dependent 
(Serres et al. 2004; Serres et al. 2005; Serres et al. 2003). However, present MRS systems suffer 
from a relatively low intrinsic sensitivity necessitating the constant infusion of considerably high 
concentrations of the labeled substrate. Until this date no methodology has been able to accurately 
measure neuronal lactate oxidation in vivo with high sensitivity. The recently synthesized 1-11C-L-
lactate (Drandarov et al. 2006) allowing the measurement of the tracer’s kinetics with high 
temporal resolution might be a promising candidate for the direct investigation of neuronal lactate 
metabolism in vivo.  
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The rationale for using radiolabeled lactate  
a) Preferential uptake of lactate in neurons 
In the mammalian brain, transport of the short chain monocarboxylate lactate is mediated by a 
diffusional, saturable cotransport with protons via specific monocarboxylate transporters (MCTs) 
(Halestrap and Price 1999). Expression of different isoforms of MCTs on astrocytes (low affinity 
transporters MCT1, MCT4 (Dimmer et al. 2000)), endothelial cells (MCT1) and neurons (high 
affinity transporter MCT2 (Broer et al. 1999) have been found (Pierre and Pellerin 2005). The 
distribution of the MCTs with their respective kinetic properties such as substrate affinity and 
transport capacity is favoring a flux of lactate from astrocytes to neurons. In addition, different 
isoforms of lactate dehydrogenase (LDH) which is the responsible enzyme for the interconversion 
of lactate and pyruvate have been located in astrocytes and neurons (Bittar et al. 1996). The LDH-
1 subunit (heart-type LDH), preferentially driving the reaction from lactate towards pyruvate, is the 
predominant LDH subunit found in neurons. Taken together, these findings support the hypothesis 
that lactate is preferentially used by neurons. 
 
b) Feasibility for the use of radiolabeled L-lactate in brain studies 
Uptake of lactate from blood into brain was already examined earlier. L-lactate, which is the 
predominant enantiomer of lactic acid in mammals, passes the blood-brain barrier at a rate of 25 % 
to 50 % of that of glucose uptake (Hassel and Brathe 2000; Knudsen et al. 1991). In line with these 
reports we calculated an EF of 30 % for 1-11C-L-lactate. This brain uptake is large enough to allow 
quantitative tracer kinetic studies. 
 
Interpretation of the 1-11C-L-lactate kinetics 
One obvious possibility is to calculate the cerebral uptake of blood-borne lactate as the product of 
K1 and blood lactate concentration (in the present study plasma lactate levels were in the range 
between 1.5 and 2.4 mmol/l). Based on the baseline data the calculated cerebral uptake of lactate 
was in the order of 0.2 μmol/min/g. This value is somewhat higher than other published values but 
in the same range (LaManna et al. 1993; Lear and Kasliwal 1991). However, anesthetic protocols 
influencing plasma lactate levels and measurement methodologies were not the same in the 
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different studies. Assuming complete oxidation the aerobic degradation of all this lactate (0.2 
μmol/min/g) would require 0.6 μmol/min/g O2, which is about 40 % of total CMRO2. This 
demonstrates that blood-borne lactate can be a major substrate in the anesthetized rat.  
More intriguing is the interpretation of the label washout rate k2. As demonstrated in Figure 7 the 
label is lost with CO2 cleaved from pyruvate by pyruvate dehydrogenase (PDH). Since the diffusion 
of CO2 into the blood stream is fast (Hawkins et al. 2006; Paulson 2002) it is likely that k2 
represents the production of CO2 and not its removal. In this case k2 would be tracing the flux 
through PDH, e.g. the production rate of acetyl CoA. Since most of the latter is oxidized in the TCA 
cycle, k2 is likely a close indicator of oxidative metabolism, and if lactate uptake is predominantly 
into neurons, of neuronal oxidative metabolism.  
In our previous study (Wyss et al. 2009), we used 11C labeled acetate to measure astrocytic 
metabolism. With the same stimulation paradigm we found a doubling of the washout rate during 
stimulation. In the present study the increase of k2 was 25 %. Since lactate enters the metabolic 
chain only one step above acetate, one would expect a similar increase of k2 for labeled acetate 
and lactate, if both were mainly taken up by astrocytes. The substantial difference in the k2 
increase of acetate and lactate therefore indicates that the 2 substrates are metabolized in 
different cell types, which leaves the neuron as the most likely candidate for lactate.  
One could also argue that most of the labeled lactate does not enter the cells at all but just enters 
and leaves interstitial space. However, this possibility is rendered very unlikely by the blockade 
experiment. After the application of 4-CIN we observed a marked decline of K1, indicating that the 
labeled lactate indeed enters cellular compartments without blockade. That parameter k2 is 
reduced to similar values as K1 suggests that under blockade it represents the backdiffusion of 
labeled lactate, and not the production of CO2 anymore.  
One could also claim that already under non-blocking conditions k2 represents backdiffusion of 
lactate. However, if this were the case one would not expect such an increase of k2 during 
stimulation.  
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General remarks 
On the methodological side the study demonstrates the advantage of the highly sensitive surface 
probe as compared to the less sensitive intracortical scintillator. Only with the high sensitivity 
system was it possible to perform 2 injections into the same animal, and only the resulting intra-
subject comparison yielded the predictedl results.  
We think that k2 is closely related to neuronal oxidative metabolism. It is clear that this refers to 
total metabolism. The study does not elucidate which substrates are oxidized, any substrate with 
pyruvate as an indermediate is possible. With regard to the astrocyte neuron lactate shuttle 
hypothesis, the study can therefore not address the open question of the neuronal fuel composition 
(glucose vs. lactate).  
 
 
Summary 
 
In this study we examined the kinetic behavior of radiolabeled L- lactate in vivo using beta probe 
instrumentation (Weber et al. 2003; Wyss et al. 2007). The kinetic properties of 1-11C-L-lactate 
make brain studies in vivo possible. We demonstrate that radiolabeled L-lactate may be used for 
the measurement of oxidative metabolism, and if lactate uptake is preferentially taken up into 
neurons, of neuronal oxidative metabolism.  Future experiments should now be designed to further 
verify the specificity of 1-11C-L-lactate to investigate neuronal oxidative metabolism. The labeling 
with 11C would also allow human studies using positron emission tomography, further enlarging the 
application field. 
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Figures of Chapter ll: 
The Kinetic Behavior of radiolabeled L-lactate in 
the Rat Brain  
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Figure ll-1. One-tissue compartment model 
 
One-tissue compartment model used to analyze CBF using H215O (A) and the kinetics of 11C- L-
lactate respectively (B). 
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Figure ll-1 
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Figure ll-2. Build-up of metabolites over 40 minutes after intravenous injection of 1-
11C-L-lactate in blood. 
 
The y-axis represents the fraction of true 1-11C-lactate in plasma. The filled circles represent 
pooled data points from all the baseline experiments (n = 6) and the solid line is the corresponding 
fit of a biexponential curve.  
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Figure ll-2 
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Figure ll-3. Kinetic modeling of 1-11C-L-lactate 
 
The measured radioactivity concentration in the brain (open circles), the model fit (black line) and 
the arterial input curve (gray line) are shown. In the inset the residuals of the fitting to the one-
tissue compartment model are shown. The absence of any bias in the distribution demonstrates 
the adequacy of the applied one-tissue compartment model.  
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Figure ll-3 
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Figure ll-4. Summary of experiments using the intracortical beta probe 
 
Inter-animal comparison in experiments with the intracortical beta probe. K1 and k2 values are 
compared between the two different groups (baseline (n = 6), stimulation (n = 7)). Boxes denote 
mean ± sd. Base = baseline; Stim = electrical infraorbital nerve stimulation. 
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Figure ll-5 
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Figure ll-5. Summary of ION stimulation experiments using the surface probe 
 
In the three panels different comparisons of the rate constants (K1, k2) between the primary 
somatosensory (S1) cortex on the stimulated side during baseline and activation (A), of S1 on the 
stimulated and on the non-stimulated side (S1n; B) and of S1n during baseline and stimulation. 
Base = baseline; Stim = electrical infraorbital nerve stimulation. 
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Figure ll-5 
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Figure ll-6. MCT blockade using 4-CIN 
 
Shown are the changes of K1 and k2 during inhibition of MCT transporters. 
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Figure ll-6 
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Figure ll-7. Scheme of the probable chain of events in the degradation of 
radiolabeled lactate in neurons 
 
1-11C-L-lactate (11C-Lac) is taken up via monocarboxylic acid transporters (MCT2) into the cell. 
Within the cell lactate is converted to 1-11C-pyruvate (11C-Pyr) and further oxidized to acety CoA 
(Ac CoA) by releasing radiolabeled CO2 (11C-CO2). This leads to removal of radiolabel before the 
entry of lactate into the tricarboxylic acid (TCA) cycle. 
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Figure ll-7 
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Abstract 
 
β+-sensitive probes are useful tools for the measurement of radiotracer kinetics in small animals. 
They allow the cost-effective development of new PET tracers and offer the possibility to 
investigate a variety of cerebral processes. The study’s main aim was the in vivo evaluation of a 
novel system for cerebral surface acquisitions. Methods: The detector system is a 0.2-mm thick 
scintillating disk of 3-mm diameter, positioned close to the cerebral surface. The study consists of 
4 subparts: (1) simulation of the detection volume, (2) direct comparison with the classic 
intracortical beta probe regarding its capability to acquire kinetic data, (3) test of the ability to 
detect local tracer accumulations during infraorbital nerve (ION) electrostimulation and (4) 
demonstration of the feasibility to measure tracer kinetics in awake animals. Kinetic data were 
fitted with a standard 18F-fluorodeoxyglucose two-tissue compartment model and a one-tissue 
compartment model for blood flow measurements using 15O-H2O. Results: The surface probe 
measurements were in good agreement with those obtained using the intracortical scintillator. ION 
electrostimulation induced a marked increase in tracer accumulation adequately detected by the 
surface probe. In the head-fixed animal, a marked change in FDG kinetics was detected between 
the awake and anesthetized state. Conclusions: The novel surface probe system proved to be a 
valuable instrument for in vivo radiotracer studies of the cerebral cortex. Its main advantages are 
an excellent counting sensitivity and the absence of any tissue damage. In addition, serial 
acquisitions of tracer kinetics in the awake animal turned out to be feasible.     
 
Key words: Awake animal, radiotracer experiments, surface beta probe, 
 
 
Acknowledgements 
The authors want to thank the Center for radiopharmaceutical science of the ETH, PSI and USZ 
for tracer production. The study was supported by the Swiss National Science Foundation (Grants 
3100A0-105804/1 and PP00B-110751/1), by the OPO-Stiftung Zürich and the Novartis Research 
Foundation. 
Chapter Ill – surface probe 
 
 
125 
 
Introduction 
 
Despite the rapid development of new functional neuroimaging tools, radiotracer experiments are 
still considered the gold standard if absolute quantification is needed. Radiotracer methods are 
widely used for the investigation of physiological and biochemical processes in the brain, such as 
receptor binding, hemodynamics, substrate use and transport processes as well as for studies in 
early drug development. The progress of research in these fields during the last few years is in part 
due to the advance of methods applicable in small animals. At present, positron emission 
tomography (PET) and beta probe measurements are the two available methods for the acquisition 
of tracer kinetics in small animals (Chatziioannou 2002; Hume and Myers 2002; Pain et al. 2000; 
Pain et al. 2002b; Rowland and Cherry 2008; Weber et al. 2003; Weber and Bauer 2004; Wyss et 
al. 2007; Wyss et al. 2009). The cost of PET is substantial and it needs high counting statistics for 
image reconstruction largely reducing temporal resolution. This makes PET often insufficient for 
kinetic modeling. The recently introduced beta probes demonstrate a valuable and cost-effective 
alternative for the detection of positrons with high temporal and reasonable spatial resolution. This 
allows the precise evaluation of radiotracer kinetics in vivo labeled with a variety of PET nuclides 
(e.g. O-15, C-11, F-18). By using the appropriate model for this radiotracer, kinetic rate constants 
of transport processes and biochemical reactions may then be estimated. However, presently 
available beta detectors suffer from various limitations. These systems, which consist of a 
scintillating crystal of 0.25 to 1 mm in diameter, are designed for acquisitions within tissue and 
often lead to tissue damage. Secondly, their relatively poor sensitivity requires the injection of high 
doses of radioactivity. This may be a problem for receptor occupancy studies because the mass of 
injected compound may lead to a marked receptor occupancy. 
In this study, we present a novel detection system designed for high sensitivity cerebral surface 
acquisitions in vivo. The probe is positioned close to the cerebral surface and thus does not cause 
any tissue damage. This new system broadens the field of application of beta probes. The aims of 
the present study were: (1) to estimate the detection volume of the surface probe using simulation, 
(2) to directly compare the novel system with the classic intracortical beta probe regarding its 
capability to acquire kinetic data, (3) to test the ability to detect local tracer accumulations during 
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infraorbital nerve (ION) electrostimulation and (4) to demonstrate the feasibility to measure tracer 
kinetics in awake animals.  
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Material and Methods 
 
Design/specifications of the system 
We used a twin probe system (Swisstrace GmbH, Zurich, Switzerland) with two photomultiplier 
tubes (Perkin Elmer, Massachusetts, USA) allowing simultaneous acquisitions of the radioactivity 
concentration in two separate brain regions. The detectors were connected with the PMTs via two 
high numerical aperture glass fibers. The detector of the surface probe consisted of organic 
scintillating crystal disks (Bicron, BF12, Newbury, OH, USA) with a thickness of 0.2 mm and a 
diameter of 3 mm embedded in a brass collimator (Figure 1A). The intracortical system consisted 
of a scintillation tip (Bicron, BF412, Newbury, OH, USA) with a length of 1 mm and a diameter of 
0.25 mm. The probes were made light-tight by applying a uniform black polymer coating. The 
limited range of beta particles within biological tissues limits detection volume to a small sphere 
centered on the scintillating tip of the probe. Monte Carlo simulations demonstrated that for F-18 
the distance required to detect 90% of the beta particles around the probe is ~1.0 mm (Pain et al. 
2002b). The apparent sensitivity of the probes under real experimental conditions was measured 
after each experiment using a standardized calibration procedure as described below. The 
theoretical sensitivity (in cps/kBq/ml) was measured after complete immersion (> 5 mm) of the 
probes in a homogenous solution with a known radioactivity concentration. Measuring the decay of 
a radioactive phantom containing F-18 over the course of several hours allowed us to measure the 
linearity of our system. Kinetic data was stored on a personal computer using a bin width of 1 
second. In the in vivo experiments acquisitions of radioactivity count rates began 10 - 30 seconds 
before tracer injection to evaluate dark counts. Thereafter, mean background counts were 
subtracted from raw data before data analysis.  
 
Calibration procedure 
Calibration measurements were performed after each experiment. A homogeneous solution with a 
known radioactivity concentration (range: 5.7 MBq/ml to 6.8 MBq/ml for F-18 and 7.1 MBq/ml to 
8.0 MBq/ml for O-15) was prepared. For the intracortical probe the calibration was performed by 
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lowering the scintillating tip 1.5 mm into the solution. To calibrate the surface probe the solution 
was covered with an ultra-thin plastic foil to prevent adhesion of solution to the detector surface. 
For the actual calibration measurement the radioactivity of the test source was measured with the 
surface probe in close contact. The factors obtained by this procedure were used to convert the 
raw data reflecting counts per second (cps) to the apparent radioactivity concentration (kBq/cc) 
measured in the experiments. Furthermore, for the surface probe, the fraction of recorded events 
attributable to gamma radiation was estimated by counting the test source additionally with the 
interposition of a 4 mm thick brass disk sufficient to absorb the 18F positrons but not attenuating 
511 keV gamma photons. 
 
Simulation of the detection volume 
Since the calibration procedure demonstrated a relatively small contribution of (gamma) photons to 
the measured signal (≤15 %), only positrons were considered. We also assumed that positrons 
only enter the scintillator through the end surface and not through the side (metal shielding). For 
the simulation the space below the scintillator was sparsed into a 3D grid (Pxyz) and the scintillator 
surface was divided into discrete squares (SQx1y1). For each point in space Pxyz, the probability that 
a positron emitted at location P would enter square SQx1y1 on the detector was calculated, yielding 
Qx1y1 (xyz). This probability depends on the spatial angle of SQx1y1 as seen from Pxyz and the 
probability that the positron reaches SQx1y1. This probability, which depends on the distance, the 
material and the emission energy of the positrons was taken from recently published data derived 
from a Monte Carlo simulation (Le Loirec and Champion 2007). The total signal recorded from 
location Pxyz is then the sum of all Qx1y1. We simulated the situation, in which the scintillator is 
placed 0.2 mm from the surface of water containing O-15, C-11 and F-18 (0.2 mm distance was 
chosen to match the thickness of the thinned skull). The sum of Qx1y1 (xyz) in the simulated volume 
was normalized to 100. 
 
Animals and radiotracer production 
All animal experiments were approved by the local veterinary authorities and were performed by 
licensed investigators. 16 female Sprague-Dawley rats (18F-fluorodeoxyglucose experiments: n =
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14; 15O-H2O: experiments n = 2) (weighing between 220 g to 280 g) were used for this study. The 
animals were kept in cages in a ventilated cabinet with standardized conditions of light (night/day-
cycle 12h/12h) and temperature and free access to food and water. Animals used for the FDG 
experiments were fasted overnight.  
18F-fluorodeoxyglucose (FDG) was obtained from the daily in-house production by the 
Radiochemistry Department of the University Hospital Zurich. For the administration of the short-
living 15O-H2O (half-life, 122.2 seconds) in high concentrations, O-15 was produced continuously in 
the cyclotron and transferred to the synthesis device (More information on this device can be found 
at http://www.swisstrace.com). The synthesis device delivered 15O-H2O at a concentration of about 
1 GBq/ml into a glass vial from where 0.5 ml were drawn into a syringe for injection.   
 
Animal Preparation 
Surgery was performed under 2.5 – 3.5% isoflurane anesthesia and involved for experiments of 
paradigm 1 and 2 the placement of an arterio-venous shunt from the right femoral artery to the 
right femoral vein and tracheotomy for mechanical ventilation. In experiments where the 
intracortical probe was used, a craniotomy and small incision of the dura was performed for the 
placement of the beta scintillator. This was not needed for the surface probe measurements, 
where the cranial bone was merely thinned to translucency. The actual experiments were 
performed under α-chloralose anesthesia (44 mg/kg bodyweight s.c.) according to the protocol of 
Bonvento et al. (Bonvento et al. 1994). The shunt was used for the continuous monitoring of 
arterial blood pressure, the injection of the radiotracers, the continuous measurement of the total 
arterial blood radioactivity, the collection of blood samples and the administration of a lethal dose 
of pentobarbital at the end of the experiment. For the recording of the total blood radioactivity the 
shunt ran through a coincidence counter (GE Medical Systems). The online arterial sampling 
procedure was established earlier and is described in detail elsewhere (Weber et al. 2002a). 
During the experiments arterial blood gases were determined regularly (AVL, Compact 3, Roche 
Diagnostics, Switzerland) and ventilation was adjusted as necessary to keep the animals within 
physiological ranges. Blood glucose levels were determined before and after each 45 minute 
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acquisition (Ektachem DT, Kodak, USA) and the mean value of the two measurements was taken 
for the quantitative glucose utilization determinations. 
For the experiment with the head-fixed animal (paradigm 3), after surgery and one week of 
recovery, the animal was trained to accept head fixation (Haiss and Schwarz 2005). Implantation 
of a head post for later head fixation was undertaken under 3% isoflurane anesthesia. After fixation 
of micro skull screws (Medartis, Basel, Switzerland) a base was built with dental cement for the 
final fixation of a standard M5 screw.  
No dental cement was applied above the right primary somatosensory cortex and the cranial bone 
was thinned at this location using a dental drill. To prevent bacterial infections after surgery the 
chronically implanted animal received oral antibiotic treatment added to the drinking water for one 
week, starting one day before surgery (Baytril® 10% oral solution, Bayer, Germany, 1 ml/1 l). 
 
Experimental protocols 
The experiments were divided into three groups: 
 
Paradigm 1) Comparison of surface probe with intracortical probe to measure cortical 
radioactivity time courses  
In a total of 8 animals the novel probe system was directly compared to the classic intracortical 
system. For this purpose the surface probe was positioned over the primary somatosensory cortex 
on one side (S1; 2 mm posterior and 6 mm lateral according to Bregma (Paxinos and Watson 
1998)). The intracortical probe was stereotactically positioned in the corresponding contralateral 
S1 and lowered 1.5 mm below the dura avoiding large blood vessels. For this paradigm two 
different radiotracers were used. In 6 animals local cerebral metabolic rates of glucose (LCMRglu) 
were determined using 18F-fluorodeoxyglucose. Only one radiotracer injection per animal was 
performed in this group (injected activity: 90 – 145 MBq). Kinetic data was acquired for a period of 
45 minutes. Directly afterwards, autoradiographic studies were performed to measure relative 
contributions of the investigated brain structure (in the present study the somatosensory cortex) 
and the surrounding tissue. To this end the last 5 minutes of the calibrated probe time activity 
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curves (calibrated as described above) were compared with the autoradiographically measured 
activity in the cortex of corresponding experiments. This yielded factors regarding the current 
underestimation of the measured tracer accumulation in the region of interest by the whole 
detection volume of the probe, an effect similar to partial volume effects observed in PET imaging.   
In 2 more animals the quantitative capability of the novel system was compared to the classical 
intracortical device performing cerebral blood flow (CBF) measurements. 180 seconds of data 
were recorded after each 15O-H2O injection. In each animal a total of 4 injections were performed 
15 minutes apart to allow for sufficient activity decay to background level. After two acquisitions 
under baseline conditions the carbonic anhydrase inhibitor acetazolamide (Diamox®; 66 mg/kg 
i.v.) was injected. Acetazolamide leads to vasodilation and thus induces a global increase in 
cerebral blood flow. Ten minutes after drug application the last two measurements were started.  
 
Paradigm 2) Quantification of localized increases of LCMRglu using the surface 
probe  
In a second group (n = 5) the ability of the novel system to detect local metabolic activations was 
evaluated. For this purpose a surface probe was positioned over S1 of each hemisphere. Two 
subsequent radiotracer injections were performed in these experiments (injection 1: 25 - 35 MBq in 
0.5 ml saline; injection 2: 80 - 100 MBq in 0.5 ml saline). Each data acquisition took 45 minutes. 
One of the two acquisitions of 18F time-course served as the baseline, whereas the other FDG 
injection was performed immediately after initiation of electrical infraorbital nerve stimulation (2 Hz, 
2 mA, pulse length 1 ms, continuous stimulation over 45 minutes). The order of baseline/activation 
conditions was balanced across the animals.  An autoradiography was performed after the second 
tracer injection as a control for the effectiveness of the applied stimulation (only in animals with 
electrostimulation performed during the second injection; n = 3).  In two additional animals both 
injections were performed during baseline conditions to control for possible drift during the 
experiment. 
  
Paradigm 3) Surface probe measurement in an awake head-fixed animal. 
The aim of this experiment was to demonstrate the feasibility of the system for measurements in 
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head-fixed non-anesthetized animals. First, the animal was carefully trained to tolerate head 
fixation. The training started one week after surgery and involved handling during the first week 
and habituation to the head holding device in the second week. In the third week, fixation of the 
animal in the head holding device started. Over the following two weeks, the duration of fixation 
was gradually increased up to 30 minutes. Finally, the tracer experiment was performed during 
head fixation. The acquisition started at the time of intraperitoneal tracer injection. After 20 
minutes, anesthesia was induced with sevoflurane 3% in a mixture of oxygen and air (30%/70%) 
and data acquisition was continued until 45 minutes after tracer injection. Two days later the 
measurement was repeated in the same animal.  
 
Autoradiographic studies 
Autoradiographies were performed as described in detail earlier (Weber et al. 2002b). In brief, 
brains were removed directly after the probe measurements, frozen in chilled isopentane and cut in 
10 µm slices. Brain slices were subsequently placed on a phosphor imaging screen (Fuji TR2025) 
together with C-14 standards (calibrated in a previous calibration experiment) for 240 min. After 
scanning the screens using a phosphor imager (Fuji BAS 1800 II, pixel size 50 μm) the data were 
converted to kBq/cc and analyzed as described below.  
 
Determination of the arterial plasma input curve in FDG experiments 
Total radioactivity in arterial blood was continuously recorded using the coincidence counter. The 
time course of the FDG concentration in arterial plasma (input curve) was then obtained by 
multiplying the whole blood values with a conversion function which had been established 
previously (Weber et al. 2002a).  
 
Data analysis 
Calculations were performed using the software PMOD (Mikolajczyk et al. 1998); PMOD 
Technologies, Adliswil, Switzerland) and Matlab (Mathworks, Natick MA, USA). 
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Calculation of the Local cerebral metabolic rate of glucose (LCMRglu) 
In the autoradiographic studies, the cerebral glucose metabolism was quantified using an 
operational equation which takes into account changing plasma glucose levels during the 
experiment (Savaki et al. 1980). The following kinetic rate constants were applied in the 
autoradiographic equation: K1 = 0.30, k2 = 0.40 and k3 = 0.68 for gray matter (Ackermann and Lear 
1989; Weber et al. 2002b). A lumped constant (LC) of 0.58 was chosen. The calculation yielded 
values for glucose consumption (µmol*min-1*g-1) in each image pixel. Regions of interest (ROIs) 
were defined over the stimulated and the contralateral cortex in ten consecutive slices. The mean 
glucose consumption in each ROI was calculated. 
The procedure for the quantification of the probe studies follows the [14C]-deoxyglucose method 
described by Sokoloff et al. (Sokoloff et al. 1977). It employs a compartmental model with two 
tissue compartments and three kinetic rate constants (K1 to k3, k4 = 0). The operational equation, 
which was fitted to the probe time activity curve additionally included a vascular fraction α as a fit 
parameter. This improved the least square fit as compared to a fixed value of α = 5% (data not 
shown).  LCMRglu values were calculated from the fitted rate constants by: LCMRglu = (K1 * k3/(k2 + 
k3))/(LC/Cplasma), where Cplasma represents the plasma glucose concentration..  
 
Model adjustments for the dual-injection paradigm 
The kinetic model was adjusted in two ways for the analysis of the dual-injection data: (1) two sets 
of rate constants (K1, k2, k3) were used in the calculation of the operational equation. The first set 
for the time until the second injection, and the second set thereafter. The least-squares fit 
procedure resulted in estimates for all 6 rate constants and the vascular fraction. (2) The correction 
function to derive plasma activity from whole blood activity was adjusted to distinguish between the 
contributions from the two injections. To this end, blood activity from the first injection was 
extrapolated using an exponential function, which was fitted to the blood activity 10 minutes before 
the second injection.    
 
Calculation of cerebral blood flow measurements (CBF) 
The basis of the calculation using the one-tissue compartment model included a partition 
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coefficient for 15O-H2O. Before data analysis, tissue time activity curves and arterial input curves 
were corrected for radioactive decay. Further details of the analysis procedure were described 
previously (Weber et al. 2003). 
 
Statistics 
Bland-Altman tests were used to assess the agreement of LCMRglu values obtained by kinetic beta 
probe measurements using the two different systems and by the static autoradiographic method 
(Bland and Altman 1986). Values are given as mean ± sd. 
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Results 
 
Performance characteristics of the new probe system 
The agreement of the decay of F-18 monitored with the beta probe and a monoexponential 
function as shown in Figure 1B demonstrates the linearity of the detector response. The mean 
sensitivity of the novel surface probe system was 0.83 ± 0.04 cps/kBq/ml using the calibration 
procedure described above. The theoretical sensitivity of the surface probe system is about 40 
times higher than the one of the intracortical system used in this study. The background (dark 
counts) ranged from 2-8 cps. Stopping the positrons using the brass disk between the 18F source 
and the detector tip reduced the count rate to 14.7 ± 4.4% of the initial value. Accordingly, the 
contribution of gamma radiation (originating from positron annihilation) to the total acquired count 
rate was about 15% for the new probe system.  
 
Simulation of detection volume 
The simulation yielded the detection volumes depicted in Figures 2A – 2C. For F-18, 95% of the 
signal was detected from within an isosurface with maximum depth of about 1 mm. As expected, 
this range is considerably larger for C-11 and O-15. As can be seen in Figures 2A – 2D, the 
sensitivity rapidly decays with depth.  
 
Animal experiments 
All time activity curves (TACs) presented are corrected for physical decay and multiplied by the 
calibration factor taking into account the respective experimental configuration for each probe 
(scintillating crystal above cortical surface or scintillating tip inside cerebral cortex).  
 
Paradigm 1) Direct comparison of the two probe systems  
Local cerebral metabolic rates of glucose consumption (LCMRglu) based on measurements with the 
two probe systems are shown in Table 1 (n = 6). The data of both probes were adequately fitted by 
the standard two-tissue compartment FDG model, as the lack of bias in the residuals indicates 
(Figures 3A and 3B). However, the higher sensitivity of the novel surface probe system led to a 
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marked decrease in the relative residual size. The Bland Altman plot in Figure 4 shows that all 
differences in LCMRglu are in the range defined by the mean ± 2 SD. Nevertheless, the values 
measured with the surface probe were on average 22% lower than the ones determined with the 
intracortical probe.   
A typical example of FDG time-activity curves recorded simultaneously with the 2 probe systems is 
demonstrated in Figure 5. In order to illustrate the similarity of the shape, the curves were 
normalized to the integral of the tissue activity between 0 and 45 minutes.  
For the CBF measurements (n = 2) a typical example of tissue time activity curves acquired with 
the two probe systems is shown in Figure 3 (panel C and D). Again the surface probe yielded a 
considerably improved signal-to-noise ratio. CBF data are shown in Table 2. The acetazolamide 
induced CBF increase was 51% with the surface probe and 48% with the intracortical probe. As 
with FDG, the absolute CBF values were somewhat smaller with the surface probe.  
 
Paradigm 2) ION electrostimulation  
To assess whether the surface probe is able to detect local increases in metabolic activity in the 
brain, electrical stimulation of the right infraorbital branch of the trigeminal nerve (ION) was 
applied. The stimulation of the ION caused the expected circumscribed increase of tracer uptake in 
the contralateral primary somatosensory cortex (S1) as shown by the autoradiographic slice in 
Figure 6. Only a weak increase in tracer uptake is noticed on the ipsilateral side. The increase was 
correctly recorded by the surface probe in all 5 experiments and was on average 60.7% at 40 
minutes. The subsequent autoradiographic evaluation showed a mean increase of 64.9%. A typical 
example of a probe acquisition during ION stimulation is presented in Figure 6. In the 2 animals 
with two FDG injections during baseline conditions stable radiotracer accumulation was observed. 
The difference in LCMRglu between the first and the second injection was 8.7% and -14.9% in the 
two animals, verifying the stability of the double-injection protocol. 
 
Paradigm 3) Determination of FDG kinetics in the awake head-fixed rat 
The animal was successfully trained for 5 weeks to tolerate the head fixation for up to 30 minutes. 
Figure 7 shows the constant increase of cerebral FDG uptake during the first 20 minutes in the
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awake animal. After induction of sevoflurane anesthesia the slope of the tissue time-activity curve 
is markedly reduced. The repetition of the acquisition two days later produced similar results (data 
not shown). 
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Discussion 
 
An increasing number of molecular imaging studies are performed with PET scanners. These 
devices allow imaging of the whole animal, if necessary several times in a longitudinal design. 
However, these PET scanners suffer from drawbacks, such as a high price and limited temporal 
resolution. The latter makes it difficult to use in a dynamic imaging design coupled with kinetic 
modeling. Another drawback of small animal PET is the requirement for anesthesia, which 
inevitably alters normal physiology. The recently introduced small beta probes for intracortical 
measurements in small animals overcame some of these problems (Ginovart et al. 2004; Pain et 
al. 2000; Pain et al. 2002b; Weber et al. 2003). They offer a cost-effective alternative whenever the 
measurement at a few locations in the brain is sufficient. They already found application in blood 
flow studies (Weber et al. 2003), metabolic studies (Millet et al. 2004; Pain et al. 2002a), receptor 
occupancy studies (Ginovart et al. 2004) and the evaluation of new radiotracers (Galineau et al. 
2006; Wyss et al. 2007; Wyss et al. 2009). All these studies were performed using thin probes 
designed for direct acquisition within the structure of interest. However, a disadvantage of these 
intracerebral probes is the potential tissue disturbance caused by their insertion.  
The present study demonstrates the suitability of the surface probe for accurate measurements of 
tracer kinetics in the rodent cerebral cortex through the thinned skull. The fact that there is no need 
for craniotomy facilitates and shortens the surgery and does not cause any tissue disturbance. The 
dura and brain remain untouched, leaving the cortex in a physiological state.   
This novel probe system was able to reliably measure kinetic data using radiotracers labeled with 
nuclides of different energies. However, values for LCMRglu and CBF were both lower in the 
surface probe measurements. Several factors could contribute to these differences which include 
probe calibration procedures, differences in the geometry and size of the detection volume. In 
addition, tissues between the surface probe and cortical surface, such as blood vessels in the dura 
and thinned bone may affect the signal measured. As previously mentioned gamma radiation may 
be yet another source for error albeit small (Pain et al. 2000; Pain et al. 2002b; Weber et al. 2003).  
Absolute values of measurements are prone to vary according to the technology used. Probably 
more important than absolute values is the reproducibility of a method and its ability to detect 
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changes associated with different activity states. Both are clearly demonstrated in this study. The 
increases in LCMRglu during ION and in CBF following acetazolamide were both detected by the 
surface probe and the percent increase was similar to that measured using autoradiography.  
The reason we used F-18 and O-15 was the different emission energy of the positrons and that 
FDG and 15O-H2O display a very different kinetic behavior. The higher emission energy of O-15 
leads to a different geometry and size of the volume of the detected positrons, as is demonstrated 
in Figure 2C. Furthermore, the kinetics of 15O-H2O are much faster than those of FDG. It was 
therefore relevant to demonstrate the suitability of the surface probe for both tracers. One of the 
most critical issues with regard to absolute quantification is the precise calibration of instruments. 
The calibration procedure should also adequately mimic the in vivo situation. It can be assumed, 
that this is somewhat more difficult in the case of the surface detector as compared to the 
intracortical probe, mainly because the position of the surface detector cannot be perfectly 
reproduced from experiment to experiment (e.g., due to the thinning of the bone, angle and 
distance of the probe relative to brain surface). 
A major advantage of the surface probe is its high sensitivity. In spite of acquiring the signal 
through several layers covering the brain, kinetic data can be acquired with low noise (Figure 3). 
This allows the injection of lower doses of radioactivity, while still yielding adequate counting 
statistics. This is especially important in receptor studies, where the mass of injected compound 
should be low in comparison to the number of receptors (Hume et al. 1998).  
Finally, another valuable feature of the surface system is its use in awake animals. This clearly 
broadens the applicability of the device given the fact that an increasing number of studies are 
performed on awake animals to avoid the disturbing effect of anesthetics on brain function (Austin 
et al. 2005; Lindauer et al. 1993; Martin et al. 2006a; Nakao et al. 2001). Our preliminary data 
acquired in one animal at two different days demonstrates the marked effect of sevoflurane 
inhalation on brain metabolism.  
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Summary 
 
In this work, we demonstrated the feasibility of a high sensitivity surface probe system for the 
measurement of radiotracer kinetics from the cerebral cortex of the rat. The system yielded 
reproducible results in the anesthetized rat. Its potential use in awake animal was demonstrated in 
a preliminary experiment. Due to its high sensitivity and low invasiveness compared to the original 
intracortical beta probe, this new device considerably widens the scope of applications of beta 
probes.  
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Table 1. Rate constants determined using a two-tissue compartment model during baseline
Animal  K1 k2 k3 LCMRglu 
number ml  min‐1 ml  tissue‐1 min‐1 min‐1 µmol  100g‐1 min‐1
Right somatosensory cortex 1 0.080 0.196 0.075 43.21
surface probe 2 0.107 0.256 0.070 45.37
3 0.122 0.304 0.098 55.88
4 0.111 0.264 0.060 35.67
5 0.106 0.304 0.108 61.90
6 0.128 0.269 0.058 45.89
mean ± sd 0.109 ± 0.02 0.266 ± 0.04 0.078 ± 0.02 47.99 ± 9.4
Left somatosensory cortex 1 0.081 0.165 0.094 57.56
intracortical probe 2 0.103 0.204 0.069 51.6
3 0.131 0.266 0.067 49.26
4 0.089 0.156 0.063 45.63
5 0.116 0.270 0.149 92.13
6 0.173 0.224 0.060 72.06
mean ± sd 0.116 ± 0.03 0.214 ± 0.05 0.084 ± 0.03 61.37 ± 17.69
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Table 2. Rate constants determined using a two-tissue compartment model during baseline
condition animal number CBF
ml min‐1 100 ml tissue‐1
Right somatosensory cortex baseline 1 35.14
surface probe 1 34.58
2 34.04
2 34.21 34.49 ± 0.5
acetazolamide 1 50.82
1 50.4
2 53.87
2 54.07 52.29 ± 1.9
Left somatosensory cortex baseline 1 37.38
intracortical probe 1 38.92
2 39.53
2 39.20 38.76 ± 0.9
acetazolamide 1 55.02
1 56.14
2 59.94
2 58.97 57.52 ± 2.3
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Figures of Chapter lll: 
Novel high sensitivity Beta Scintillator for Cortical 
Measurements of Radiotracer Kinetics in the 
Rodent Brain 
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Figure lll-1. The novel surface probe: Design and linearity 
 
(A) Schematic of the novel probe. Dimensions are given in mm. The scintillation crystal and the 
optical fiber are covered by a tungsten shell. (B) Semi-logarithmic plot of the physical decay of F-
18 detected by the novel surface probe. Linearity of the device is evident from the high agreement 
of the measured data (open circles) with the theoretical decay (black line). 
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Figure Ill-1 
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Figure lll-2. Calculated detection volumes 
 
Results from the detection volume simulations. (A) – (C): Detection fraction from a plane 
representing the sum projection along the Y-direction for F-18 (A), C-11 (B) and O-15 (C). The thin 
black lines represent the 95% isolines. The sum of all values in the simulated volume was set to 
100. (D) The curves depict the normalized detection fraction for sums in planes along the depth (Z-
direction) for the simulated isotopes. The vertical straight lines represent the 95% thresholds.         
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Figure Ill-2 
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Figure lll-3. Examples of acquired radiotracer data 
 
Typical examples of tissue time activity curves acquired by the original intracortical probe (A, C) 
and the surface probe (B, D) using two different radiotracers, 18F-FDG (A, B) and 15O-H2O (C, D). 
The radioactivity concentration in plasma (light gray line) in whole blood (dark gray line) and the 
model fit (black line) are also shown. The goodness-of-fit is demonstrated by the random 
distribution of the residuals (inset). Due to the increased sensitivity of the new system, signal-to-
noise ratio is increased leading to an improved model fit illustrated by the narrower range of 
variability of the residuals.  
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Figure Ill-3 
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Figure lll-4. Comparison of intracortical and surface probe measurements 
 
Bland Altman plot to evaluate the agreement of the probe measurements in 6 animals using 18F-
FDG. The middle line represents the mean of two measurements in the same animal using the two 
different probe systems, the border dashed lines the mean +/- 2 sd, respectively. 
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Figure Ill-4. 
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Figure lll-5. Normalized 18F-FDG accumulation measured by the two probe systems 
 
Time activity curves of 18F-FDG accumulation in the rat‘s somatosensory cortex normalized to the 
integral of tissue activity between 0 and 45 minutes. Shown is the measurement in a single animal 
acquired on one side with the intracortical system (open circles) and homotopically on the 
contralateral hemisphere with the surface probe system (filled gray circles).  
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Figure Ill-5 
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Figure lll-6. Glucose utilization during ION stimulation 
 
Decay-corrected tissue time activity curves acquired by the surface probe system during electrical 
infraorbital nerve stimulation in one animal are demosntrated. As shown in the autoradiogram, 
contralateral to the stimulation site (arrow, gray squares in the graph) accumulation of 
18
F-FDG 
was increased compared to the ipsilateral hemisphere (open circles in the graph). The radioactivity 
concentration in plasma (gray line) and in whole blood (black line) is also shown.  
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Figure Ill-6 
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Figure lll-7. Acquisition in the awake, head-fixed animal 
 
The decay-corrected time activity curve shows a steep slope in the awake state which 
considerably flattens after the induction of anesthesia with the fast-acting volatile anesthetic 
sevoflurane at time point 20 minutes.  
 
  
Chapter Ill – surface probe 
 
 
159 
 
Figure Ill-7 
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Implications and Future directions 
 
The original intent of the project was to address the following specific questions: 
 
What is the first pass extraction fraction of the different tracers? 
What compartment model describes the cerebral kinetics of the tracers? 
How does tracer kinetics change during electrical and pharmacological interventions? 
How do these changes reflect neuronal lactate metabolism and astrocytic oxidative metabolism? 
 
All these general questions were answered and discussed in detail by the individual studies in their 
respective sections. Overall, the project led to a better understanding of the characteristics of the 
applied radiotracers, rendering their application and indication easier. Furthermore, our research 
may provide a novel approach to the compartmentalized brain energy metabolism using 
radiotracer kinetics. In addition, the project went a step further and introduced a novel beta probe 
refining the methodology used to measure tracer kinetics with high temporal resolution. The 
individual studies were already discussed in detail in their respective sections. Here, I would like to 
stress some final points concerning selected aspects of the project. More specifically, I would like 
to highlight the work’s significance regarding neurometabolic research development, the potential 
implications for a better understanding of metabolism-related neuroimaging using FDG, and its 
clinical relevance. 
 
Beta probe studies in neurometabolic research 
In general, the project aimed to pave the way for the beta probe methodology in the field of 
neurometabolic research. It is the first study that uses radiotracer kinetic measurements to collect 
information from separate metabolic compartments in the living brain. Indeed, beta probe 
acquisitions have already been employed for brain metabolism-related work, beside their use in 
receptor studies (Galineau et al. 2006; Ginovart et al. 2004; Wyss et al. 2007) and  measurements 
of cerebral blood flow (Weber et al. 2003). However, studies about brain metabolism were highly 
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limited and the only tracer used so far together with kinetic beta probe measurements was 18F-
fluorodeoxyglucose (Millet et al. 2004; Pain et al. 2002a). As stated in the introduction, cerebral 
glucose utilization measurements using 18F-fluorodeoxyglucose are integrating all separate 
metabolic compartments without offering site-specific information. However, site-specific 
information is crucial for a better understanding of a highly compartmentalized system such as 
brain metabolism. Supported by the experimental results, we could show for the first time 
compartmental information of brain metabolism (for summary see Figure 10) using kinetic 
measurements. In previous years, radiotracer experiments were performed using the ex vivo 
autoradiographic approach that measures the distribution of nuclides and metabolites produced 
within brain tissue after injection of the labeled compounds (Berl and Frigyesi 1968; Berl and 
Frigyesi 1969; Cremer 1970). Although these studies increased our knowledge about the 
compartmentalization of brain metabolism (for a review see (Hertz 2004)), this approach, in 
contrast to kinetic approaches, did not offer the possibility to deduce transport and binding rates of 
the tracer under study. A significant advantage of beta probe experiments is that the 
characteristics of the dynamic process can be inferred. Analysis of such data acquired with high 
temporal resolution results in robust rate constants of the processes involved in the biological 
system under study. Kinetic data can theoretically also be obtained by the analysis of serial 
tomographic images from PET studies, but they may not provide accurate information about tracer 
uptake of different brain regions, especially in rodents (Chatziioannou 2002). Furthermore, the use 
of this sophisticated imaging technique is not as cost-effective as beta probe measurements. 
Robust kinetic data, such as those delivered by probe measurements, help to calculate 
quantitative results from kinetic modeling. A high temporal resolution is also mandatory for 
multiple-injection protocols, which can be carried out easily using beta probes. In addition, they can 
be combined with other modalities, such as laser Doppler flowmetry, magnetic resonance imaging, 
and nuclear magnetic resonance (Desbree et al. 2004; Desbree et al. 2007). In the future, 
especially the combination with MRS may result in valuable new insights into compartmentalized 
brain metabolism. The most common MRS approach relies on the infusion of 13C-enriched 
substrates (e.g. glucose, acetate) and the measurement of label incorporation into brain 
metabolites (Escartin et al. 2006). It has the unique property to specifically identify the molecule
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and the atomic position at which the 13C label accumulates. These properties enabled MRS to 
contribute significantly to the knowledge about the neuron/astrocyte dialogue. The advantage of 
this very fine biochemical probing also has some drawbacks. On the one hand, the intrinsic 
sensitivity of the method is low making the detection of trace amounts of the label impossible, on 
the other hand, the spatial resolution is limited rendering the exploration of focal neural activation 
difficult.    
Finally, the recent demonstration of the use of radiosensitive intracortical probes in the mouse is 
worth mentioning (Desbree et al. 2008). The increasing number of murine disease models and 
genetically altered mice will further enlarge the field of application for beta probe studies. 
 
Compartmentation of brain metabolism 
There still exists remarkable controversy regarding proportional contributions of the single 
compartments to the overall cerebral metabolism. Especially the percentage of oxidative and 
glycolytic energy metabolism is ambiguous (for review see (Hertz 2004)). The main difficulty is the 
fact that the proportions are not fixed during different states of activity. This is in agreement with 
previous observations made using different methods and stimuli, which consistently showed that 
oxygen consumption increases less than glucose utilization and CBF (Fox and Raichle 1986; Fox 
et al. 1988) during activation compared to baseline state. In the present work I disclosed the 
potential of radiotracer methodology to capture oxidative metabolism in segregated cellular 
populations, i.e. neurons and astrocytes. By using lactate and acetate radiolabeled with a positron-
emitter, it was possible to investigate, for the first time, aspects of specific metabolic compartments 
of the brain in vivo in a dynamic manner. In future studies these methods will offer the possibility to 
further investigate the respective size of these compartments at varying neuronal activity and 
pharmacological manipulations of the involved energetic pathways. This can help to better 
understand some mechanisms of regulation. 
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Figure 10. Schematic summary of the compartmental investigation of brain metabolism using 11C-
acetate and 11C-L-lactate 
The two tracers used in the present project allow the examination of specific metabolic steps within the two 
main oxidative compartments of brain metabolism. A.) 11C-L-lactate, which is preferred by neurons, traces 
particularly neuronal uptake of lactate via the monocarboxylic acid transporter (MCT2) and its 
decarboxylation via pyruvate to acetyl CoA. B.) The astrocyte-specific compound 11C-acetate traces the 
degradation to CO2 via the TCA cycle and with it specifically astrocytic oxidative metabolism. Yellow 
asterisks indicate the path of the label (C-11). Formed CO2 will then leave brain tissue by diffusion across 
the BBB and removal by the blood system (not shown in the diagram). 
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Neuroimaging using 18F-fluorodeoxyglucose 
Beside cerebral blood flow also energy metabolism is functionally coupled to brain activity which 
forms the fundament of modern neuroimaging methods (for review see (Raichle 2003; Raichle and 
Mintun 2006)). Neuroscience without this variety of brain imaging modalities is not conceivable 
anymore. As stated above, 18F-FDG is the main radiotracer used in functional metabolism-related 
neuroimaging with positron emission tomography so far. The determination of glucose utilization 
using 18F-FDG is an unspecific measure integrating all the spatially separated compartments and 
does not offer any site-specific information. Recently it was shown that glial cells take up 2DG only 
to a slightly lower extent than neurons (Nehlig et al. 2004) although glial energy need was 
calculated to be in a range of 5 to 20% (Attwell and Laughlin 2001; Gjedde et al. 2002). This 
obvious discrepancy was explained by the notion that the major part of glucose is processed via 
anaerobic glycolysis only in astrocytes. However, our study shows that also astrocytes exhibit 
significant aerobic metabolism at baseline (in the range of 20% of total cerebral oxygen 
consumption). Further studies about size and share of different metabolic compartments will help 
for a better understanding of the nature and meaning of findings obtained in the past using 
deoxyglucose methodology. Site-specific quantities are crucial for a significant improvement in our 
understanding of a highly compartmentalized system, such as brain metabolism. Also the debate 
about the existence of the ANLS can profit from the development and application of new 
approaches for the compartmental investigation of brain energy metabolism. 
 
Energy metabolism and neurological diseases 
For a variety of neurological and non-neurological diseases severe metabolic deficits in the brain 
have been documented (Martin et al. 2007; Mason et al. 2006; Mosconi 2005; Simpson et al. 1994; 
Sonnewald and Kondziella 2003).  On the one hand, the metabolic impairment can be very clear 
as during ischemia, where the energy supply is acutely disrupted leading to death of brain cells. 
On the other hand, the defect can be as small as a single gene mutation causing the dysfunction of 
a key enzyme or transport step involved in brain metabolism leading to neuronal dysfunction, such 
as glycogen storage disease or pyruvate dehydrogenase deficiency. Research focusing on 
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mechanisms and effects of such diseases can profit from new approaches. In this respect, further 
research in a more clinical and disease-related environment can profit twofold from the present 
project. Firstly, the radiotracer kinetic measurements by the beta probe technology can be easily 
translated into a clinical setup by using positron emission tomography. This is an elegant example 
of accelerating the way from preclinical to clinical studies. Secondly, a better understanding of 
pathogenesis of the diseased brain may pave the way for new therapeutic approaches. Metabolic 
alterations often precede structural changes and the detection of these changes may prove critical 
in assessing disease progression and treatment. Based on our work, it is particularly interesting 
that many neurological diseases exhibit mitochondrial dysfunction (Beal 2000; Beal et al. 1993). 
Therefore the measurement of the astrocytic or neuronal CMRO2 may prove beneficial for the 
investigation of such diseases.  
 
In summary, the present project demonstrates the possibility to measure distinct parameters of 
separate metabolic compartments in the intact brain using radiotracer kinetics. The fact that 
radiotracer kinetic measurements are in principle smoothly transferable to humans further 
increases the relevance of this work. The application of radiotracer measurements using nuclear 
medicine devices may prove important in the future for both, a better understanding of 
neuron/astrocyte contribution to energy metabolism, and the ability to obtain novel insights into the 
pathomechanisms of various pathologies.  
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